<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomedicines</journal-id><journal-id journal-id-type="iso-abbrev">Biomedicines</journal-id><journal-id journal-id-type="publisher-id">biomedicines</journal-id><journal-title-group><journal-title>Biomedicines</journal-title></journal-title-group><issn pub-type="epub">2227-9059</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7148454</article-id><article-id pub-id-type="doi">10.3390/biomedicines8030060</article-id><article-id pub-id-type="publisher-id">biomedicines-08-00060</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Viral Vector-Based Melanoma Gene Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hromic-Jahjefendic</surname><given-names>Altijana</given-names></name><xref ref-type="aff" rid="af1-biomedicines-08-00060">1</xref></contrib><contrib contrib-type="author"><name><surname>Lundstrom</surname><given-names>Kenneth</given-names></name><xref ref-type="aff" rid="af2-biomedicines-08-00060">2</xref><xref rid="c1-biomedicines-08-00060" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-biomedicines-08-00060"><label>1</label>Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina; <email>ahromic@ius.edu.ba</email></aff><aff id="af2-biomedicines-08-00060"><label>2</label>PanTherapeutics, CH 1095 Lutry, Switzerland</aff><author-notes><corresp id="c1-biomedicines-08-00060"><label>*</label>Correspondence: <email>lundstromkenneth@gmail.com</email>; Tel.: +41-79-776-6351</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2020</year></pub-date><volume>8</volume><issue>3</issue><elocation-id>60</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2020</year></date><date date-type="accepted"><day>11</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Gene therapy applications of oncolytic viruses represent an attractive alternative for cancer treatment. A broad range of oncolytic viruses, including adenoviruses, adeno-associated viruses, alphaviruses, herpes simplex viruses, retroviruses, lentiviruses, rhabdoviruses, reoviruses, measles virus, Newcastle disease virus, picornaviruses and poxviruses, have been used in diverse preclinical and clinical studies for the treatment of various diseases, including colon, head-and-neck, prostate and breast cancer as well as squamous cell carcinoma and glioma. The majority of studies have focused on immunotherapy and several drugs based on viral vectors have been approved. However, gene therapy for malignant melanoma based on viral vectors has not been utilized to its full potential yet. This review represents a summary of the achievements of preclinical and clinical studies using viral vectors, with the focus on malignant melanoma.</p></abstract><kwd-group><kwd>melanoma</kwd><kwd>cancer</kwd><kwd>vector delivery</kwd><kwd>gene therapy</kwd><kwd>immunotherapy</kwd><kwd>clinical trials</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-biomedicines-08-00060"><title>1. Introduction</title><p>Melanoma, or malignant melanoma, represents a cancer type that develops in melanocytes known as pigment-containing cells [<xref rid="B1-biomedicines-08-00060" ref-type="bibr">1</xref>]. Since the beginning of the 21st century, melanoma has remained one of the most fatal malignancies. Most patients, when diagnosed early, are treated by local surgical excision following sentinel lymph node biopsy [<xref rid="B1-biomedicines-08-00060" ref-type="bibr">1</xref>]. The incidence varies by country, skin phenotype and sun exposure. It mostly affects young and middle-aged female populations (below the age of 50 years), but more males are affected from the age of 55 onwards [<xref rid="B1-biomedicines-08-00060" ref-type="bibr">1</xref>]. In men the incidence of melanoma is three times higher than in women by the age of 75. Ultraviolet (UV) light is known to be the main cause of malignant melanoma. A history of sunburn in childhood or adolescence has been suggested to be directly associated with the development of melanoma. Other risk factors include the number of melanocytic nevi, family history and genetic background. It has also been confirmed that patients with a previous history of melanoma are more prone to develop multiple primary melanomas [<xref rid="B1-biomedicines-08-00060" ref-type="bibr">1</xref>]. In contrast, other environmental factors like alcohol or tobacco consumption have not been associated with melanoma development [<xref rid="B2-biomedicines-08-00060" ref-type="bibr">2</xref>]. </p><p>Skin melanoma has generally been classified according to the origin of the sun exposure, the degree of cumulative UV exposure, age at the time of diagnosis, types of oncogenic drivers and the mutational load [<xref rid="B2-biomedicines-08-00060" ref-type="bibr">2</xref>]. It is known that B-Raf proto-oncogene (BRAF), neurofibromin 1 (NF1) and NRAS mutations, together with a high mutational load related to UV exposure, are the main genetic drivers [<xref rid="B3-biomedicines-08-00060" ref-type="bibr">3</xref>]. Cases of periodic sun exposure are usually associated with BRAF<sup>V600E</sup> and a lower mutational load [<xref rid="B2-biomedicines-08-00060" ref-type="bibr">2</xref>]. It is important to mention that each melanoma subtype may evolve from different precursor lesions, which can involve different gene mutations as well as different transformational stages [<xref rid="B3-biomedicines-08-00060" ref-type="bibr">3</xref>].</p><p>Current medical treatments include various methods. Most patients with recently diagnosed melanoma have early-stage disease and can be treated by surgical excision, which is curative in the majority of cases. Some treatment methods involve lymph node biopsies in addition to standard surgical excision. Unfortunately, 10% of all melanoma cases are diagnosed at an advanced/late stage and are already metastatic, including visceral and brain metastases [<xref rid="B2-biomedicines-08-00060" ref-type="bibr">2</xref>,<xref rid="B3-biomedicines-08-00060" ref-type="bibr">3</xref>,<xref rid="B4-biomedicines-08-00060" ref-type="bibr">4</xref>,<xref rid="B5-biomedicines-08-00060" ref-type="bibr">5</xref>]. These patients have a poor prognosis and the probability of treatment success is lower. For patients with advanced stage disease, revolutionary therapy agents including RAF (Rapidly Accelerated Fibrosarcoma) and MEK (Mitogen-activated Protein Kinase) kinase inhibitors as well as immune checkpoint inhibitors like anti-CTLA4 and anti-PD1 have been approved, in 2011 and 2016, respectively [<xref rid="B5-biomedicines-08-00060" ref-type="bibr">5</xref>,<xref rid="B6-biomedicines-08-00060" ref-type="bibr">6</xref>,<xref rid="B7-biomedicines-08-00060" ref-type="bibr">7</xref>,<xref rid="B8-biomedicines-08-00060" ref-type="bibr">8</xref>]. Anti-PD1 and anti-CTLA4 antibodies (nivolumab, pembrolizumab and ipilimumab) as well as BRAF and MEK inhibitors (vemurafenib and trametinib) have shown promising results in clinical trials [<xref rid="B9-biomedicines-08-00060" ref-type="bibr">9</xref>,<xref rid="B10-biomedicines-08-00060" ref-type="bibr">10</xref>,<xref rid="B11-biomedicines-08-00060" ref-type="bibr">11</xref>,<xref rid="B12-biomedicines-08-00060" ref-type="bibr">12</xref>,<xref rid="B13-biomedicines-08-00060" ref-type="bibr">13</xref>,<xref rid="B14-biomedicines-08-00060" ref-type="bibr">14</xref>,<xref rid="B15-biomedicines-08-00060" ref-type="bibr">15</xref>,<xref rid="B16-biomedicines-08-00060" ref-type="bibr">16</xref>]. Today, the presence of the BRAF<sup>V600E</sup> mutation is verified in clinical settings, since it determines the correct treatment strategy. Mutations like NRAS, NF1, CKIT, CDKN2A and PTEN have not been included in clinical practice yet.</p><p>Immunotherapy and kinase inhibitors are known as backbones for second-line systemic chemotherapy [<xref rid="B17-biomedicines-08-00060" ref-type="bibr">17</xref>]. In the past, chemotherapy represented the treatment option for advanced melanoma. Although attempts to improve patient responses by combination therapy failed, it is still used for palliative treatment of progressed melanomas [<xref rid="B18-biomedicines-08-00060" ref-type="bibr">18</xref>]. Dacarbazine, an alkylating agent, was approved by the FDA in 1974 for standard chemotherapy treatment of metastatic melanoma [<xref rid="B19-biomedicines-08-00060" ref-type="bibr">19</xref>]. Despite moderate results, dacarbazine has been used as the sole standard of care, recently (in clinical trials) in combination with other chemotherapies and immunotherapies (ClinicalTrials.gov) [<xref rid="B20-biomedicines-08-00060" ref-type="bibr">20</xref>]. Temozolomide (TMZ), an active metabolite of dacarbazine, has been applied in advanced melanoma [<xref rid="B20-biomedicines-08-00060" ref-type="bibr">20</xref>].</p><p>Electrochemotherapy (ECT) combines two cytotoxic drugs (cisplatin and bleomycin) with high-intensity electric pulses, which enhances the delivery of the drug into cells [<xref rid="B21-biomedicines-08-00060" ref-type="bibr">21</xref>,<xref rid="B22-biomedicines-08-00060" ref-type="bibr">22</xref>]. This approach has been used for the treatment of cutaneous and subcutaneous melanoma nodules [<xref rid="B23-biomedicines-08-00060" ref-type="bibr">23</xref>]. The overall response was 85%, and no major negative adverse events were reported [<xref rid="B21-biomedicines-08-00060" ref-type="bibr">21</xref>]. Photodynamic therapy (PDT) is a light-based therapy. It represents a promising adjuvant treatment and can be used as a palliative method of choice for patients with stage III/IV cutaneous metastatic melanomas [<xref rid="B24-biomedicines-08-00060" ref-type="bibr">24</xref>]. PDT is considered a minimally invasive procedure that requires a photosensitizer. Absorption is superior in metabolically active tissues [<xref rid="B24-biomedicines-08-00060" ref-type="bibr">24</xref>]. The method applies non-toxic compounds, which create reactive oxygen species (ROS) when combined with oxygen [<xref rid="B25-biomedicines-08-00060" ref-type="bibr">25</xref>]. ROS does irreversible damage to tumor cells and tumor-associated blood vessels, and contributes to the activation of various antitumor, immune and inflammatory responses [<xref rid="B25-biomedicines-08-00060" ref-type="bibr">25</xref>,<xref rid="B26-biomedicines-08-00060" ref-type="bibr">26</xref>,<xref rid="B27-biomedicines-08-00060" ref-type="bibr">27</xref>,<xref rid="B28-biomedicines-08-00060" ref-type="bibr">28</xref>]. Although PDT can be applied to both nonmalignant and malignant diseases, several reports show that PDT alone has only limited efficacy in melanoma [<xref rid="B22-biomedicines-08-00060" ref-type="bibr">22</xref>]. To improve PDT results, certain protective mechanisms, like pigmentation and oxidative stress resistance, need to be overcome [<xref rid="B29-biomedicines-08-00060" ref-type="bibr">29</xref>,<xref rid="B30-biomedicines-08-00060" ref-type="bibr">30</xref>]. The combination of PDT and dacarbazine chemotherapy displayed resistance reduction in pigmented and unpigmented metastatic melanomas [<xref rid="B31-biomedicines-08-00060" ref-type="bibr">31</xref>]. On the other hand, combination of PDT and immunotherapy may increase the effect of eradication of the initial tumor and decrease in melanoma recurrence [<xref rid="B29-biomedicines-08-00060" ref-type="bibr">29</xref>].</p><p>In the context of oncolytic viruses, their selective replication triggers tumor cell death and vector spread into neighboring cells, providing an interesting approach for cancer therapy [<xref rid="B32-biomedicines-08-00060" ref-type="bibr">32</xref>]. Immunization studies in experimental models have employed a wide range of viral vectors based on adenoviruses, alphaviruses, herpes simplex viruses, coxsackie viruses and vaccinia viruses, targeting cancer types like glioblastoma, colon, cervix, and lung cancer as well as melanoma [<xref rid="B33-biomedicines-08-00060" ref-type="bibr">33</xref>,<xref rid="B34-biomedicines-08-00060" ref-type="bibr">34</xref>]. The first virus-based melanoma drug was approved by the FDA in 2015 [<xref rid="B35-biomedicines-08-00060" ref-type="bibr">35</xref>]. </p></sec><sec id="sec2-biomedicines-08-00060"><title>2. Viral Vector Systems</title><p>Today, both viral and non-viral vectors have been subjected to preclinical and clinical studies in the field of gene therapy. A brief description of different viral vector systems for gene therapy applications is presented below, with a special emphasis on melanoma treatment. The range of viral vectors is very broad. It includes delivery vehicles developed for both short-term and long-term expression, including single-stranded (ss) and double-stranded (ds) RNA and DNA genome viruses [<xref rid="B36-biomedicines-08-00060" ref-type="bibr">36</xref>]. The major features of the viral vectors, and examples of their applications in gene therapy, are presented in <xref rid="biomedicines-08-00060-t001" ref-type="table">Table 1</xref>. </p></sec><sec id="sec3-biomedicines-08-00060"><title>3. Viral Vectors for Melanoma Treatment</title><p>As previously described, a broad range of oncolytic viruses have been evaluated for cancer gene therapy [<xref rid="B107-biomedicines-08-00060" ref-type="bibr">107</xref>]. The specific targeting and killing of tumor cells and the simultaneous stimulation of the immune system have made oncolytic viruses attractive delivery vehicles [<xref rid="B108-biomedicines-08-00060" ref-type="bibr">108</xref>,<xref rid="B109-biomedicines-08-00060" ref-type="bibr">109</xref>,<xref rid="B110-biomedicines-08-00060" ref-type="bibr">110</xref>]. This dual action promotes tumor regression as well as the induction of immune responses through innate and adaptive components. On the other hand, naturally occurring, ubiquitous, non-enveloped dsRNA viruses have shown generally mild infection in humans, and specific replication and cytopathogenicity in transformed cells, which possess active Ras signaling pathways [<xref rid="B111-biomedicines-08-00060" ref-type="bibr">111</xref>,<xref rid="B112-biomedicines-08-00060" ref-type="bibr">112</xref>]. Their specificity for Ras transformed cells and their relatively non-pathogenic nature in humans make them attractive anticancer therapy candidates [<xref rid="B111-biomedicines-08-00060" ref-type="bibr">111</xref>,<xref rid="B112-biomedicines-08-00060" ref-type="bibr">112</xref>]. This approach may lead to the recognition and removal of systemic disease and the prevention of tumor return [<xref rid="B113-biomedicines-08-00060" ref-type="bibr">113</xref>]. A summary of completed and ongoing clinical trials is presented in <xref rid="biomedicines-08-00060-t002" ref-type="table">Table 2</xref>. </p><sec id="sec3dot1-biomedicines-08-00060"><title>3.1. Melanoma Treatment Using Herpes Simplex Virus Type 1</title><p>The prototype drug for virotherapy is an attenuated herpes simplex virus type 1 (HSV-1), which is engineered to express the human granulocyte&#x02013;macrophage colony-stimulating factor (GM&#x02013;CSF) [<xref rid="B35-biomedicines-08-00060" ref-type="bibr">35</xref>]. The approved drug known as talimogene laherparepvec (TVEC) has the trade name Imlygic<sup>&#x000ae;</sup>. TVEC showed two mechanisms of action, one being the oncolytic effect of infecting and killing tumor cells at the local injection site, and the other being the immunotherapeutic effect through induction of local and systemic immune responses [<xref rid="B114-biomedicines-08-00060" ref-type="bibr">114</xref>]. </p><p>TVEC replicates in tumor cells, which results in lysis and release of soluble tumor-associated antigens and viral pathogens. Migration and maturation of dendritic cells is induced by local GM-CSF expression, leading to ingestion of dissolvable tumor antigens and apoptotic tumor cells. The dendritic cells are transported to the nearest lymph nodes, where antigens initiate a systemic immune response, specifically in CD4+ and CD8+ helper and cytotoxic T-cells. However, the response rate in metastases is lower than in injected tumors, which reflects insufficient effector T-cell expansion. The other reason could be the lack of efficacy at distant sites. To overcome this limitation, combination therapy with TVEC and immune checkpoint blockers might provide better results [<xref rid="B35-biomedicines-08-00060" ref-type="bibr">35</xref>]. </p><p>Generally, local lytic TVEC infection in tumor cells leads to the release of various proteins, such as interferons, chemokines, danger-associated molecular pattern (DAMP), and pathogen-associated molecular pattern (PAMP). These can provide more favorable surroundings for stimulation of anti-tumor immune responses [<xref rid="B115-biomedicines-08-00060" ref-type="bibr">115</xref>]. Cancer cell lysis discharges tumor-associated neoantigens for processing by dendritic cells, which are activated by TVEC-encoded GM&#x02013;CSF. This could lead to stimulation of anti-tumor CD8+ T-cell responses against unrecognized antigens and this effect has been clinically demonstrated [<xref rid="B115-biomedicines-08-00060" ref-type="bibr">115</xref>].</p><sec id="sec3dot1dot1-biomedicines-08-00060"><title>3.1.1. Preclinical Studies with HSV</title><p>TVEC showed strong lytic activity against various human tumors, including malignant melanoma. Melanoma patients treated with TVEC exhibited accumulation of CD8+ T-cells in injected lesions and decrease of CD4+ FoxP3+ regulatory cells as well as CD14+ myeloid-derived suppressor cells [<xref rid="B115-biomedicines-08-00060" ref-type="bibr">115</xref>]. Together, these findings demonstrate the effect of TVEC in the infection process and the driving of transgene expression in different cell types.</p></sec><sec id="sec3dot1dot2-biomedicines-08-00060"><title>3.1.2. Clinical Trials of TVEC in Melanoma Treatment</title><p>The ICP34.5-deleted HSV-1 vector was engineered to express beta-galactosidase [<xref rid="B122-biomedicines-08-00060" ref-type="bibr">122</xref>]. Strong expression was observed in the brain and dorsal root ganglia, with only minor toxicity, which indicates that deletion of the HSV-1 neurovirulence gene eliminates neurotoxicity. However, it preserves tolerable infectivity, in order to allow dominant trans-gene expression in neural tissue [<xref rid="B122-biomedicines-08-00060" ref-type="bibr">122</xref>]. The ICP34.5-deleted HSV-1 vector was more effective with respect to lysis in human breast cancer cells than in a mixed culture of autologous hematopoietic cells [<xref rid="B123-biomedicines-08-00060" ref-type="bibr">123</xref>]. </p><p>The first human study of TVEC was a phase I trial, involving 30 patients [<xref rid="B123-biomedicines-08-00060" ref-type="bibr">123</xref>]. Patients were chosen according to cutaneous and subcutaneous metastases from melanoma, breast cancer or squamous cell carcinoma of the head and neck [<xref rid="B123-biomedicines-08-00060" ref-type="bibr">123</xref>]. Local intratumoral administration of virus was applied in order to reduce toxicity compared to systemic delivery, and this was well tolerated with only few adverse effects, like local inflammation and flu-like symptoms. Local reactions were dose-limited (10<sup>7</sup> pfu/mL) and baseline HSV serologic status did not influence the effect of TVEC. However, a priming dose of 10<sup>6</sup> pfu/mL was established, followed 3 weeks later by increasing the dose to 10<sup>8</sup> pfu/mL every 2 weeks until disease progression was confirmed or unacceptable toxicity occurred [<xref rid="B123-biomedicines-08-00060" ref-type="bibr">123</xref>]. Although objective responses were not seen in the trial, viral replication as well as GM&#x02013;CSF expression and HSV-antigen-associated necrosis were observed in melanoma, breast, head and neck cancer. Six patients manifested flattening of injected/un-injected tumors, and in four patients, systemic immune responses were obtained.</p><p>In a phase II trial, 50 patients with metastatic melanoma at stage IIIC or IV were enrolled [<xref rid="B124-biomedicines-08-00060" ref-type="bibr">124</xref>]. Systemic treatment was carried out for 74% of the patients with advanced melanoma. Patients were injected with 10<sup>6</sup> pfu/mL, and the dose was increased 3 weeks later to 10<sup>8</sup> pfu/mL. Treatment continued every 2 weeks for a maximum of 24 treatments [<xref rid="B124-biomedicines-08-00060" ref-type="bibr">124</xref>]. TVEC was again well tolerated and the toxicity was primarily narrowed to flu-like symptoms and local inflammation. The overall survival rate was 58% at one year and 52% at two years [<xref rid="B9-biomedicines-08-00060" ref-type="bibr">9</xref>].</p><p>After encouraging results were obtained from the phase II trials, a phase III trial (OPTiM) was conducted for patients with stage IIIB to IV melanoma [<xref rid="B117-biomedicines-08-00060" ref-type="bibr">117</xref>]. Patients either received intralesional TVEC or GM&#x02013;CSF subcutaneously, at 125 mg/m<sup>2</sup> daily for 14 days in 28-day cycles. Since the frequency of pseudo-progression with TVEC was high, treatment discontinuation was not required before 24 weeks. After this period, treatment continued. The primary endpoint was a durable response rate (DRR), defined as the percentage of patients experiencing a response lasting more than 6 months and beginning within the first 12 months of treatment. The most common adverse effects upon application of TVEC were fatigue, chills, nausea and local injection symptoms. Statistical analysis revealed that overall survival in the TVEC arm was superior for patients with stage III and IV M1a melanoma (metastases only in skin or lymph nodes) and for treatment of naive patients with <italic>p</italic> &#x0003c; 0.001 in both comparisons. According to these remarkable results, TVEC became the first oncolytic virus-based therapy which showed significant clinical benefits in a phase III trial [<xref rid="B114-biomedicines-08-00060" ref-type="bibr">114</xref>] leading to the FDA approval of TVEC as a monotherapy in October 2015 [<xref rid="B35-biomedicines-08-00060" ref-type="bibr">35</xref>].</p></sec></sec><sec id="sec3dot2-biomedicines-08-00060"><title>3.2. Melanoma Treatment Using Retroviruses/Lentiviruses</title><p>Retroviruses and lentiviruses are ssRNA, which can provide long-term transgene expression by integration into the host genome. They have frequently been used as gene therapy vectors for indications such as glioma [<xref rid="B77-biomedicines-08-00060" ref-type="bibr">77</xref>,<xref rid="B78-biomedicines-08-00060" ref-type="bibr">78</xref>], and breast [<xref rid="B81-biomedicines-08-00060" ref-type="bibr">81</xref>], gastric [<xref rid="B82-biomedicines-08-00060" ref-type="bibr">82</xref>], liver [<xref rid="B83-biomedicines-08-00060" ref-type="bibr">83</xref>], pancreatic [<xref rid="B84-biomedicines-08-00060" ref-type="bibr">84</xref>], and hematologic [<xref rid="B85-biomedicines-08-00060" ref-type="bibr">85</xref>] cancers. One limitation of using retroviruses such as Moloney murine leukemia virus (MoMLV) for gene therapy is the requirement of cell division for transduction and integration [<xref rid="B125-biomedicines-08-00060" ref-type="bibr">125</xref>]. In contrast, lentiviruses are capable of transduction of both dividing and non-dividing cells.</p><sec id="sec3dot2dot1-biomedicines-08-00060"><title>3.2.1. Preclinical Studies with Retroviruses/Lentiviruses</title><p>Although retroviruses have demonstrated potential for treating chronic diseases such as severe combined immunodeficiency (SCID) in children [<xref rid="B126-biomedicines-08-00060" ref-type="bibr">126</xref>], fewer studies have been conducted for cancer. For instance, recombinant retrovirus vectors expressing GM&#x02013;CSF and IL-4 showed high-level expression in cultured primary glioma cells, which lasted for 14 days and could therefore present an attractive approach for immunotherapy [<xref rid="B77-biomedicines-08-00060" ref-type="bibr">77</xref>]. However, in recent years, lentiviral vectors have replaced conventional retroviruses in gene therapy. For instance, a lentivirus carrying the EGFP reporter gene provided long-term expression in DU145 and PC3 human prostate cell lines and in vivo in pre-established and orthotopic tumors [<xref rid="B127-biomedicines-08-00060" ref-type="bibr">127</xref>]. In the context of melanoma, a lentiviral vector expressing the VP22-CD/5-FC suicide gene system demonstrated superior antitumor activity in a murine uveal melanoma model [<xref rid="B128-biomedicines-08-00060" ref-type="bibr">128</xref>]. In another study, a lentivirus vector expressing RNAi sequences targeting the MAT2B gene, the regulatory subunit of methionine adenosyltransferase resulted in suppressed growth, colony formation and induced apoptosis in A375 and Mel-RM malignant melanoma cell lines, and affected tumor growth in a xenograft model in vivo [<xref rid="B129-biomedicines-08-00060" ref-type="bibr">129</xref>]. Moreover, antisense non-coding mitochondrial RNA (ASncmtRNAs) was downregulated by a lentivirus vector expressing short hairpin RNA (shRNA), which induced apoptosis in murine B16F10 and human A375 melanoma cell lines, significantly reduced B16F10 tumor growth in vivo, and reduced the number of lung metastases in a tail vein assay [<xref rid="B130-biomedicines-08-00060" ref-type="bibr">130</xref>]. </p></sec><sec id="sec3dot2dot2-biomedicines-08-00060"><title>3.2.2. Clinical Trials of Retroviruses/Lentiviruses for Melanoma Treatment</title><p>Related to lentivirus-based clinical trials, 30 children and adults with relapsed acute lymphoblastic leukemia (ALL) were treated with a lentiviral vector-based chimeric antigen receptor T (CAR-T), targeting CD19 (CTL019), which resulted in sustained remission with a 6-month event-free survival rate of 67% and an overall survival rate of 78% [<xref rid="B131-biomedicines-08-00060" ref-type="bibr">131</xref>]. The treatment of relapsed and refractory ALL was efficient, with a high remission rate lasting for up to 24 months. In preparation for lentivirus-based clinical trials, monocyte-derived conventional dendritic cells (ConvDCs) were transduced using a tricistronic lentivirus vector, expressing GM&#x02013;CSF, IL-4 and the melanoma antigen tyrosine-related protein 2 (TRP2), to overcome the difficulties in manufacturing and potency of ConvDCs [<xref rid="B132-biomedicines-08-00060" ref-type="bibr">132</xref>]. The feasibility of this approach was demonstrated with monocytes from five advanced melanoma patients indicating that a simpler GMP-compliant method for manufacturing individualized DC vaccines with a higher specificity against melanoma is possible. In another approach, to improve ex vivo manufacturing of engineered T cells, isolated human CD8+ T cells from healthy donors were transduced with a lentivirus vector expressing the gp100-specific tumor antigen-specific T cell receptor (TCR) in the presence of a novel chemical lentiviral transduction enhancer (Lentiboost) [<xref rid="B133-biomedicines-08-00060" ref-type="bibr">133</xref>]. It was demonstrated that antigen-specific secretion of tumor necrosis factor (TNF) and interferon-&#x003b3; (IFN-&#x003b3;) occurred in the transduced cells and significant cytotoxicity was detected in the antigen-positive tumor cells, showing the potential of lentivirus-based cancer immunotherapy.</p><p>The success of CAR-T based lentivirus therapy for hematological cancers such as ALL has also triggered treatment of solid tumors [<xref rid="B134-biomedicines-08-00060" ref-type="bibr">134</xref>]. However, with tumors, the transition might be limited by therapeutic barriers such as CAR-T cell expansion, persistence, trafficking, and fate. In the context of melanoma, the first results from CAR-T cell therapy could not reproduce the findings from the treatment of hematological diseases [<xref rid="B135-biomedicines-08-00060" ref-type="bibr">135</xref>]. Issues to be addressed include the lack of migration of CAR-T cells from blood vessels to the tumor site, as well as the immunosuppressive tumor microenvironment within solid tumors, before this technology can be successfully applied for melanoma treatment.</p></sec></sec><sec id="sec3dot3-biomedicines-08-00060"><title>3.3. Melanoma Treatment Using Reoviruses</title><p>The nonenveloped dsRNA Reovirus Serotype 3-Dearing Strain known as Reolysin has been shown to replicate in specifically transformed cells possessing an activated RAS signaling pathway, which makes it a potential candidate for anticancer therapy [<xref rid="B136-biomedicines-08-00060" ref-type="bibr">136</xref>,<xref rid="B137-biomedicines-08-00060" ref-type="bibr">137</xref>,<xref rid="B138-biomedicines-08-00060" ref-type="bibr">138</xref>]. The inhibition of dsRNA-activated protein kinase (PKR) in Ras-activated cells inhibits autophosphorylation of PKR, permitting viral translation and oncolysis in tumor cells [<xref rid="B36-biomedicines-08-00060" ref-type="bibr">36</xref>,<xref rid="B114-biomedicines-08-00060" ref-type="bibr">114</xref>]. As Ras pathway activation occurs in approximately 60% of metastatic melanoma patients, it provides a great opportunity for Reolysin testing in malignancy treatment [<xref rid="B139-biomedicines-08-00060" ref-type="bibr">139</xref>,<xref rid="B140-biomedicines-08-00060" ref-type="bibr">140</xref>].</p><sec id="sec3dot3dot1-biomedicines-08-00060"><title>3.3.1. Preclinical Studies with Reoviruses</title><p>It has been observed that some tumor cells and spontaneously transformed cell lines show favorable sensitivity toward reoviruses [<xref rid="B141-biomedicines-08-00060" ref-type="bibr">141</xref>]. Other studies have revealed that intratumoral injection of reoviruses leads to regression of v-erbB-transformed NIH 3T3 or human U87 glioblastoma tumors in 80% of SCID mice. Moreover, multiple reovirus injections resulted in total tumor regression in 65% of immune-competent C3H mice [<xref rid="B142-biomedicines-08-00060" ref-type="bibr">142</xref>]. The oncolytic capacity of reoviruses allows their application as single drugs targeting various types of cancers. It was confirmed that reoviruses can kill six human breast cancer cell lines (SK-BR-3, KPL4, MDA-MB-453, CRL1500, MCFT and MDA-MB-231) expressing HER-2, but not the breast cancer cell line Hs578Bst, which did not show HER-2 expression [<xref rid="B143-biomedicines-08-00060" ref-type="bibr">143</xref>]. Favorable anticancer effects have also been demonstrated in immunocompetent mouse models in the presence of cyclosporine A or anti-CD4/anti-SD8 antibodies as immunosuppressant agents [<xref rid="B144-biomedicines-08-00060" ref-type="bibr">144</xref>]. This shows the potential for reoviruses to be implemented for the treatment of a wide range of cancer types.</p></sec><sec id="sec3dot3dot2-biomedicines-08-00060"><title>3.3.2. Clinical Trials of Reoviruses in Melanoma Treatment</title><p>Reovirus-based monotherapy has been conducted for solid tumors including soft-tissue sarcomas, melanoma, breast cancer and head and neck cancer [<xref rid="B145-biomedicines-08-00060" ref-type="bibr">145</xref>]. One study included 18 patients and was mainly designed to verify the safety and tolerability of reovirus intralesional administration [<xref rid="B146-biomedicines-08-00060" ref-type="bibr">146</xref>]. Monitoring was done over a period of six weeks. The toxic effects were measured according to the criteria of the National Cancer Institute Clinical Trials Group. The tumor responses were measured using the Response Evaluation Criteria in Solid Tumors. After the trial period of six weeks, one patient showed complete response (CR), two demonstrated partial responses (PRs), four patients had stable disease (SD) and ten showed progressive disease (PD) [<xref rid="B146-biomedicines-08-00060" ref-type="bibr">146</xref>]. However, the results indicated that intralesional reovirus monotherapy was safe, well tolerated and did not reach dose-limiting toxicity. Local administration of reovirus in phase I/II malignant melanoma studies was as well tolerated as monotherapy [<xref rid="B147-biomedicines-08-00060" ref-type="bibr">147</xref>,<xref rid="B148-biomedicines-08-00060" ref-type="bibr">148</xref>]. Intravenous reovirus monotherapy was applied in a malignant melanoma phase II trial in 21 patients receiving a 3 &#x000d7; 10<sup>10</sup> 50% tissue-culture infective dose (TCID50) once every 60 min on days 1&#x02013;5 every four weeks [<xref rid="B73-biomedicines-08-00060" ref-type="bibr">73</xref>]. Clinical benefits as CR or PR were monitored for eight weeks. One patient demonstrated extensive tumor necrosis (75%&#x02013;90%) in two metastatic lesions after two treatment cycles, whereas no other patient met the criteria for CR or PR [<xref rid="B119-biomedicines-08-00060" ref-type="bibr">119</xref>]. Moreover, reovirus was detected in two out of 13 biopsies containing melanoma metastases. The findings from the phase II trial further support the positive clinical outcome obtained from phase I studies [<xref rid="B149-biomedicines-08-00060" ref-type="bibr">149</xref>,<xref rid="B150-biomedicines-08-00060" ref-type="bibr">150</xref>]. Furthermore, 2 out of 13 patients showed productive reoviral replication in melanoma metastases. Unfortunately, the trial could not progress as initially planned, as the clinical objective of having two or more patients reaching CR or PR was not achieved. According to these results, the phase II trial did not support the application of reovirus as a monotherapy for metastatic melanoma, but rather as part of a combination therapy with other therapeutic or chemotherapeutic agents [<xref rid="B146-biomedicines-08-00060" ref-type="bibr">146</xref>]. </p></sec></sec><sec id="sec3dot4-biomedicines-08-00060"><title>3.4. Current Stage of Melanoma Treatment Using Coxsackievirus CVA21</title><p>CVA21, a member of the Picornaviridae family, is a nonenveloped ssRNA enterovirus enclosed in an icosahedral capsid. Two major subgroups, A and B, have been characterized in murine models [<xref rid="B151-biomedicines-08-00060" ref-type="bibr">151</xref>]. Subgroup A contains 23 serotypes, with their main impact on skeletal muscles, while subgroup B contains six serotypes affecting a broad range of tissue types [<xref rid="B149-biomedicines-08-00060" ref-type="bibr">149</xref>]. Their clinical significance in humans reflects their responsibility for mild upper respiratory tract infections spread by aerosol transmission [<xref rid="B152-biomedicines-08-00060" ref-type="bibr">152</xref>]. The oncolytic CVA21 is commercially available as CAVATAK&#x02122; based on the wild-type Kuykendall strain [<xref rid="B153-biomedicines-08-00060" ref-type="bibr">153</xref>]. Modelling of the attachment mechanisms and cell internalization has indicated that other group A serotypes may have similar oncolytic potential [<xref rid="B154-biomedicines-08-00060" ref-type="bibr">154</xref>]. The CVA21 infection is characterized by attachment to the intracellular adhesion molecule-1 (ICAM-1), the primary receptor for attachment, and to the decay-accelerating factor (DAF), the secondary receptor for attachment [<xref rid="B155-biomedicines-08-00060" ref-type="bibr">155</xref>]. ICAM-1 is a viral receptor common for the Picornaviridae family. Although DAF is expressed on almost all cells, its primary role is regulation of complement responses [<xref rid="B155-biomedicines-08-00060" ref-type="bibr">155</xref>]. Since the attachment of CVA21 to DAF is not sufficient for host cell infection, DAF is considered to act as a membrane receptor, which accumulates the virus at the cell surface and optimizes viral entry via ICAM-1 [<xref rid="B156-biomedicines-08-00060" ref-type="bibr">156</xref>]. The discovery of CVA21 and its lysis of cancer cells was mainly achieved through research conducted on ICAM-1 and DAF receptors, and comparisons between various cancer cell lines and nonmalignant tissues. It has also been shown for melanoma as well as multiple myeloma, malignant glioma, breast, colon, endometrial and pancreatic cancer cell lines [<xref rid="B157-biomedicines-08-00060" ref-type="bibr">157</xref>,<xref rid="B158-biomedicines-08-00060" ref-type="bibr">158</xref>]. </p><sec id="sec3dot4dot1-biomedicines-08-00060"><title>3.4.1. Preclinical Studies with CVA21 </title><p>Overexpression of ICAM-1 and DAF in malignant melanoma compared to normal cells represents the potential for CVA21 applications [<xref rid="B159-biomedicines-08-00060" ref-type="bibr">159</xref>]. Upregulation of ICAM-1 in melanoma is well studied, and it has been considered a relevant marker in disease prognosis [<xref rid="B160-biomedicines-08-00060" ref-type="bibr">160</xref>]. It has been suggested that ICAM-1 is responsible for metastasis generation, as it facilitates cell-cell interactions between malignant melanocytes and circulating lymphocytes [<xref rid="B95-biomedicines-08-00060" ref-type="bibr">95</xref>]. Upregulation of ICAM-1 in melanoma could be a potential target for CVA21 therapy as has been reported [<xref rid="B158-biomedicines-08-00060" ref-type="bibr">158</xref>]. These results were obtained from the human melanoma chemotherapy-resistant Mel-CV and Mel-FH cell lines. The primary melanoma MM200 cell line showed in vitro oncolysis [<xref rid="B161-biomedicines-08-00060" ref-type="bibr">161</xref>]. In vivo, it was shown that mouse tumor xenografts were reduced after treatment with CVA21 through intratumoral, intravenous and intraperitoneal administration [<xref rid="B86-biomedicines-08-00060" ref-type="bibr">86</xref>]. Later, it was demonstrated that other group A coxsackie viruses had similar oncolytic properties and were not sensitive to neutralizing antibodies against CVA21. This opens the possibility of multivalent approaches through the application of different serotypes [<xref rid="B156-biomedicines-08-00060" ref-type="bibr">156</xref>]. </p></sec><sec id="sec3dot4dot2-biomedicines-08-00060"><title>3.4.2. Clinical Trials Using CVA21 </title><p>Investigations of CVA21 have progressed to clinical trials; phase I safety trials were completed in 2009 [<xref rid="B162-biomedicines-08-00060" ref-type="bibr">162</xref>]. Fifty-seven patients with unresectable stage IIIc-IVM1c melanoma were subjected to an intratumoral dose of 3 &#x000d7; 10<sup>8</sup> TCID<sub>50</sub> of CAVATAK&#x02122; on days 1, 3, 5 and 8 in a phase II trial. A phase II trial using CVA21 enrolled 57 patients with unresectable stage IIIc-IVM1c melanoma. The therapy continued every three weeks, with a total of six injections followed by sequential tumor biopsies for injected and non-injected lesions, where monitoring of viral replication and virus-induced immune activation was observed. The obtained DRRs were 28.1 % (16 out of 57 patients) and 38.6% (21 out of 57 patients) and showed immune-related progression-free survival six months after the treatment [<xref rid="B163-biomedicines-08-00060" ref-type="bibr">163</xref>]. Additionally, the first results from phase Ib reported the combination therapy of CAV21 with ipilimumab in patients with advanced melanoma [<xref rid="B151-biomedicines-08-00060" ref-type="bibr">151</xref>]. A cohort of 26 patients was chosen, where 13 individuals had previously been treated with anti-PD-1 antibody. All 26 of them received 3 &#x000d7; 10<sup>8</sup> TCID<sub>50</sub> CVA21 on days 1, 3, 5, 8 and 22, followed by six injections of ipilimumab (3 mg/kg), beginning on day 22. The ORR was 38% and the disease control rate (DCR) was 88%, including CR, PR and stable disease SD [<xref rid="B164-biomedicines-08-00060" ref-type="bibr">164</xref>]. According to a phase II study, intralesional admission of CVA21 can substantially influence the dynamics of the tumor micro-environment, which can be observed by an increase in immune cell infiltrates and immune-related response genes [<xref rid="B116-biomedicines-08-00060" ref-type="bibr">116</xref>]. </p></sec></sec><sec id="sec3dot5-biomedicines-08-00060"><title>3.5. Current Stage of Melanoma Treatment Using Newcastle Disease Virus (NDV)</title><p>The LaSota strain of NDV has been modified by reverse genetics in order to be applied as a recombinant vaccine vector [<xref rid="B165-biomedicines-08-00060" ref-type="bibr">165</xref>]. The distinct advantages of NDV relate to the host restriction and lack of pre-existing immunity in humans, where high-titer NDV replication can be obtained in certain cell lines suitable for human vaccine development [<xref rid="B166-biomedicines-08-00060" ref-type="bibr">166</xref>]. Reverse genetics was employed in order to optimize foreign gene expression from NDV vectors. This was achieved through application of red fluorescence protein (RFP) at multiple sites downstream of the nucleocapsid (NP), P, M, fusion (F), hemagglutinin-neuramidase (HN) and large polymerase (L) genes [<xref rid="B167-biomedicines-08-00060" ref-type="bibr">167</xref>]. The sequential transcription mechanism was confirmed according to the RFP expression levels. In a similar way, the avirulent NDV strain TS09-C was modified using reverse genetics for GFP expression after gene insertion upstream of the NP, M and L genes, resulting in remarkable expression [<xref rid="B168-biomedicines-08-00060" ref-type="bibr">168</xref>]. The specific replication in tumor cells makes NDV attractive for cancer therapy [<xref rid="B89-biomedicines-08-00060" ref-type="bibr">89</xref>].</p><sec id="sec3dot5dot1-biomedicines-08-00060"><title>3.5.1. Preclinical Studies with NDV</title><p>Regarding preclinical studies, the NDV strain 73-T caused complex tumor regression in athymic mice containing fibrosarcoma xenografts [<xref rid="B169-biomedicines-08-00060" ref-type="bibr">169</xref>]. Even a single intratumoral administration caused complete regression and multiple administrations provided superior efficacy [<xref rid="B169-biomedicines-08-00060" ref-type="bibr">169</xref>]. Intratumoral administration of NDV vectors expressing G-CSF, IL-2 or TNF resulted in decreases in tumor growth in a colon carcinoma model, and the majority of treated mice showed complete and long-lasting remission. The NDV LaSota strain showed superior suppression of tumor growth in comparison to a recombinant rNDV vector when both expressed IL-2 and IL-15 [<xref rid="B80-biomedicines-08-00060" ref-type="bibr">80</xref>]. NDV-IL-15 significantly increased the levels of IFN-&#x003b3; compared to NDV-IL-2. The survival rate of the NDV-IL15 group was 26.67 % higher than the rate of NDV-IL2 group [<xref rid="B80-biomedicines-08-00060" ref-type="bibr">80</xref>]. Another study using recombinant NDV expressing IL-2 and TRAIL (tumor necrosis factor-related apoptosis inducing ligand) increased anti-neoplastic activity through induction of apoptosis and induced proliferation of CD4+ and CD8+ cells in mice, which reduced tumor development [<xref rid="B83-biomedicines-08-00060" ref-type="bibr">83</xref>]. Prolonged survival was reported in mice carrying hepatocellular carcinoma (HCCs) and melanoma cells, which received the rNDV-IL-2-TRAIl vector [<xref rid="B83-biomedicines-08-00060" ref-type="bibr">83</xref>]. In order to reduce the environmental risk of NDV, which is toxic in birds, and the neurotoxicity of VSV (Vesicular stomatitis virus), a hybrid vector was engineered, where the VSV G protein was replaced with NDV hemagglutinin-neuraminidase (HN) and further modified by fusion proteins. The hybrid demonstrated lower neurotoxicity, and no virulence in embryonated chicken eggs was detected [<xref rid="B170-biomedicines-08-00060" ref-type="bibr">170</xref>].</p></sec><sec id="sec3dot5dot2-biomedicines-08-00060"><title>3.5.2. Clinical Trials using NDV</title><p>NDV has been applied in various clinical trials for cancer therapy. A long-term survival in phase II trials of ovarian, stomach and pancreatic cancers was observed [<xref rid="B171-biomedicines-08-00060" ref-type="bibr">171</xref>]. Three hundred and thirty-five individuals with colorectal cancer were immunized with NDV vectors in a phase III trial, which provided prolonged survival and improved life quality [<xref rid="B120-biomedicines-08-00060" ref-type="bibr">120</xref>]. However, in a randomized double-blind phase II/III trial in melanoma patients no significant differences between patients vaccinated with NDV and the placebo group were seen [<xref rid="B172-biomedicines-08-00060" ref-type="bibr">172</xref>]. </p></sec></sec><sec id="sec3dot6-biomedicines-08-00060"><title>3.6. Current Stage of Melanoma Treatment Using Alphaviruses</title><p>Alphaviruses have been subjected to vector engineering procedures, including Semliki Forest virus (SFV), Sindbis virus (SIN) and Venezuelan equine encephalitis virus (VEE) [<xref rid="B173-biomedicines-08-00060" ref-type="bibr">173</xref>,<xref rid="B174-biomedicines-08-00060" ref-type="bibr">174</xref>,<xref rid="B175-biomedicines-08-00060" ref-type="bibr">175</xref>]. RNA replicons as well as recombinant alphavirus particles and DNA/RNA layered plasmids have been applied for cancer therapy. In one study, mice were immunized with SFV-LacZ RNA, which resulted in tumor regression [<xref rid="B58-biomedicines-08-00060" ref-type="bibr">58</xref>]. Since oncolytic alphaviruses occur naturally, they have been isolated and engineered from avirulent SFV strains. Using the SFV-VA7 avirulent strain, high infection rates and lysis of malignant cells were achieved, and solitary intravenous infusion prompted critical tumor relapse in a melanoma SCID mouse model [<xref rid="B60-biomedicines-08-00060" ref-type="bibr">60</xref>]. </p><sec id="sec3dot6dot1-biomedicines-08-00060"><title>3.6.1. Preclinical Studies with Alphaviruses </title><p>Tumor targeting represents one important consideration when using alphaviruses for cancer treatment. It has been reported that SIN particles possess natural tumor targeting. After subcutaneous administration of SIN-IL12 in mice implanted with tumor xenografts the tumor load was reduced to 6.2% of control mice [<xref rid="B176-biomedicines-08-00060" ref-type="bibr">176</xref>]. On the other hand, studies on SFV particles showed no tumor targeting [<xref rid="B101-biomedicines-08-00060" ref-type="bibr">101</xref>]. To address this shortcoming, liposome-encapsulated SFV-LacZ particles were engineered in order to provide tumor targeting in SCID mice after systemic delivery [<xref rid="B177-biomedicines-08-00060" ref-type="bibr">177</xref>]. </p><p>Alphavirus vectors have shown promising potential in cancer treatment because of easy and fast production of high-titer recombinant particles and the possibility of administration of transcribed RNA or layered plasmid DNA [<xref rid="B178-biomedicines-08-00060" ref-type="bibr">178</xref>]. Another aspect that makes alphaviruses attractive is their capacity for extreme cytoplasmic RNA replication and transient high-level recombinant protein expression. Compared to an adenovirus vector, SFV-based HPV E6-E7 immunization required 100- to 1000-fold lower doses to evoke similar therapeutic responses in a mouse model [<xref rid="B179-biomedicines-08-00060" ref-type="bibr">179</xref>]. Similarly, oncolytic alphaviruses and their tumor-targeting properties provided superior tumor growth inhibition and eradication. Another important aspect is that alphaviruses do not possess widespread immunity in human and animal populations, despite some epidemics reported for certain alphaviruses such as SFV, SIN and VEE [<xref rid="B178-biomedicines-08-00060" ref-type="bibr">178</xref>]. </p><p>Alphavirus DNA replicon vectors have been evaluated in animal models. In this context, expression of the HSV type 1 glycoprotein B from a SIN DNA vector elicited a broad range of immune responses, which included virus-specific antibodies, cytotoxic T cells and protection against lethal virus challenges in mice at a significantly lower dose compared to a conventional plasmid [<xref rid="B180-biomedicines-08-00060" ref-type="bibr">180</xref>]. In another study, an SFV DNA replicon vector carrying the bovine viral diarrhea virus (BVDV) p80 (NS3) was administered into the quadricep muscles of BALB/c mice; this generated significant cytotoxic T-lymphocyte activity and cell-mediated immune responses against cytopathic and noncytopathic BVDV [<xref rid="B181-biomedicines-08-00060" ref-type="bibr">181</xref>]. It was observed that, in general, lower doses (100-fold to 1000-fold) of alphavirus DNA replicon were needed to achieve the same level of response observed for conventional DNA vaccines [<xref rid="B181-biomedicines-08-00060" ref-type="bibr">181</xref>,<xref rid="B182-biomedicines-08-00060" ref-type="bibr">182</xref>]. </p><p>RNA-based delivery has also proven efficient in vaccine development [<xref rid="B58-biomedicines-08-00060" ref-type="bibr">58</xref>]. It has been reported that a single intramuscular injection of 0.1 &#x000b5;g SFV-LacZ replicon RNA generated antigen-specific antibody and CD8+ T cell responses in vaccinated animals [<xref rid="B58-biomedicines-08-00060" ref-type="bibr">58</xref>]. The immunization provided protection in mice challenged with colon tumor cells. In another approach, a SIN RNA replicon expressing the rabies virus glycoprotein gene was applied for immunization of mice using only 10 &#x000b5;g of SIN-Rab-G RNA [<xref rid="B183-biomedicines-08-00060" ref-type="bibr">183</xref>]. Compared to a conventional rabies DNA vaccine and the Rabipur commercial cell culture vaccine, similar cellular and humoral immune responses and protection against rabies were obtained.</p></sec><sec id="sec3dot6dot2-biomedicines-08-00060"><title>3.6.2. Clinical Trials with Alphaviruses</title><p>In attempts to improve efficacy and to provide tumor targeting, SFV particles were encapsulated in liposomes [<xref rid="B121-biomedicines-08-00060" ref-type="bibr">121</xref>]. Intravenous administration of encapsulated SFV particles expressing IL-12 (LipoVIL12) enhanced IL-12 plasma levels by 10-fold in a phase I clinical trial in kidney carcinoma and melanoma patients. The encapsulation enhanced tumor targeting as well as prevented recognition by the host immune system, which allowed re-administration without evoking immune responses against SFV [<xref rid="B121-biomedicines-08-00060" ref-type="bibr">121</xref>]. Additional clinical trials have been conducted with alphaviruses for various cancer types and viral diseases, demonstrating good safety of the immunization process, although further dose optimization is still required. This represents a promising aspect for further development of alphavirus applications in melanoma treatment.</p></sec></sec></sec><sec sec-type="conclusions" id="sec4-biomedicines-08-00060"><title>4. Conclusions and Future Aspects</title><p>In summary, oncolytic viruses have proven powerful in several preclinical tumor models and clinical studies. They have provided suppression of tumor growth and regression as well as increased quality of life in patients (<xref rid="biomedicines-08-00060-t002" ref-type="table">Table 2</xref>). The range of oncolytic viruses (adenoviruses, AAV, HSV, Coxsackievirus, NDV, retroviruses, etc.) allows modifications related to expression, packaging and host range tropism. However, further improvements in dose optimization and therapeutic efficacy are needed, especially in the area of melanoma therapy. Today, many virus vectors have demonstrated promising efficacy in combination with standard melanoma therapy, including immunotherapy, either in the form of MEK and BRAF inhibitors or in combination with chemotherapy (dacarbazine and cisplatin). It seems that no single-virus vector system shows superiority and, therefore, development of different expression systems in parallel is recommended. In conclusion, advances in gene therapy and the approval of several drugs will contribute to virus-based therapy potentially becoming a key asset in modern clinical applications, including related to malignant melanoma. </p></sec></body><back><notes><title>Funding</title><p>This research received no external funding. </p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. </p></notes><ref-list><title>References</title><ref id="B1-biomedicines-08-00060"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastrelli</surname><given-names>M.</given-names></name><name><surname>Tropea</surname><given-names>S.</given-names></name><name><surname>Rossi</surname><given-names>C.R.</given-names></name><name><surname>Alaibac</surname><given-names>M.</given-names></name></person-group><article-title>Melanoma: Epidemiology, risk factors, pathogenesis, diagnosis and classification</article-title><source>In Vivo</source><year>2014</year><volume>28</volume><fpage>1005</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">25398793</pub-id></element-citation></ref><ref id="B2-biomedicines-08-00060"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y.</given-names></name></person-group><article-title>The role and necessity of sentinel lymph node biopsy for invasive melanoma</article-title><source>Front. Med. (Lausanne)</source><year>2019</year><volume>6</volume><pub-id pub-id-type="doi">10.3389/fmed.2019.00231</pub-id><?supplied-pmid 31696119?><pub-id pub-id-type="pmid">31696119</pub-id></element-citation></ref><ref id="B3-biomedicines-08-00060"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>Z.</given-names></name><name><surname>Yousaf</surname><given-names>N.</given-names></name><name><surname>Larkin</surname><given-names>J.</given-names></name></person-group><article-title>Melanoma epidemiology, biology and prognosis</article-title><source>EJC Suppl.</source><year>2013</year><volume>11</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.ejcsup.2013.07.012</pub-id><?supplied-pmid 26217116?><pub-id pub-id-type="pmid">26217116</pub-id></element-citation></ref><ref id="B4-biomedicines-08-00060"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candido</surname><given-names>S.</given-names></name><name><surname>Rapisarda</surname><given-names>V.</given-names></name><name><surname>Marconi</surname><given-names>A.</given-names></name><name><surname>Malaponte</surname><given-names>G.</given-names></name><name><surname>Bevelacqua</surname><given-names>V.</given-names></name><name><surname>Gangemi</surname><given-names>P.</given-names></name><name><surname>Scalisi</surname><given-names>A.</given-names></name><name><surname>Mccubrey</surname><given-names>J.A.</given-names></name><name><surname>Maestro</surname><given-names>R.</given-names></name><name><surname>Spandidos</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure</article-title><source>Oncol. Rep.</source><year>2014</year><volume>31</volume><fpage>1079</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.3892/or.2014.2977</pub-id><?supplied-pmid 24424406?><pub-id pub-id-type="pmid">24424406</pub-id></element-citation></ref><ref id="B5-biomedicines-08-00060"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastian</surname><given-names>B.C.</given-names></name></person-group><article-title>The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia</article-title><source>Annu. Rev. Pathol.</source><year>2014</year><volume>9</volume><fpage>239</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-012513-104658</pub-id><?supplied-pmid 24460190?><pub-id pub-id-type="pmid">24460190</pub-id></element-citation></ref><ref id="B6-biomedicines-08-00060"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtin</surname><given-names>J.A.</given-names></name><name><surname>Patel</surname><given-names>H.N.</given-names></name><name><surname>Cho</surname><given-names>K.-H.</given-names></name><name><surname>LeBoit</surname><given-names>P.E.</given-names></name></person-group><article-title>Distinct sets of genetic alterations in melanoma</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>353</volume><fpage>2135</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050092</pub-id><?supplied-pmid 16291983?><pub-id pub-id-type="pmid">16291983</pub-id></element-citation></ref><ref id="B7-biomedicines-08-00060"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shain</surname><given-names>A.H.</given-names></name><name><surname>Bastian</surname><given-names>B.C.</given-names></name></person-group><article-title>From melanocytes to melanomas</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>345</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.37</pub-id><?supplied-pmid 27125352?><pub-id pub-id-type="pmid">27125352</pub-id></element-citation></ref><ref id="B8-biomedicines-08-00060"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>E.</given-names></name><name><surname>Pagliara</surname><given-names>M.M.</given-names></name><name><surname>Orteschi</surname><given-names>D.</given-names></name><name><surname>Dosa</surname><given-names>T.</given-names></name><name><surname>Sammarco</surname><given-names>M.G.</given-names></name><name><surname>Caputo</surname><given-names>C.G.</given-names></name><name><surname>Petrone</surname><given-names>G.</given-names></name><name><surname>Rindi</surname><given-names>G.</given-names></name><name><surname>Zollino</surname><given-names>M.</given-names></name><name><surname>Blasi</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Pembrolizumab as first-line treatment for metastatic uveal melanoma</article-title><source>Cancer Immunol. Immunother.</source><year>2019</year><volume>68</volume><fpage>1179</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1007/s00262-019-02352-6</pub-id><pub-id pub-id-type="pmid">31175402</pub-id></element-citation></ref><ref id="B9-biomedicines-08-00060"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodi</surname><given-names>F.S.</given-names></name><name><surname>O&#x02019;Day</surname><given-names>S.J.</given-names></name><name><surname>McDermott</surname><given-names>D.F.</given-names></name><name><surname>Weber</surname><given-names>R.W.</given-names></name><name><surname>Sosman</surname><given-names>J.A.</given-names></name><name><surname>Haanen</surname><given-names>J.B.</given-names></name><name><surname>Gonzalez</surname><given-names>R.</given-names></name><name><surname>Robert</surname><given-names>C.</given-names></name><name><surname>Schadendorf</surname><given-names>D.</given-names></name><name><surname>Hassel</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1003466</pub-id><pub-id pub-id-type="pmid">20525992</pub-id></element-citation></ref><ref id="B10-biomedicines-08-00060"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauschild</surname><given-names>A.</given-names></name><name><surname>Grob</surname><given-names>J.-J.</given-names></name><name><surname>Demidov</surname><given-names>L.V.</given-names></name><name><surname>Jouary</surname><given-names>T.</given-names></name><name><surname>Gutzmer</surname><given-names>R.</given-names></name><name><surname>Millward</surname><given-names>M.</given-names></name><name><surname>Rutkowski</surname><given-names>P.</given-names></name><name><surname>Blank</surname><given-names>C.U.</given-names></name><name><surname>Miller</surname><given-names>W.H.</given-names></name><name><surname>Kaempgen</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>358</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60868-X</pub-id><pub-id pub-id-type="pmid">22735384</pub-id></element-citation></ref><ref id="B11-biomedicines-08-00060"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McArthur</surname><given-names>G.A.</given-names></name><name><surname>Chapman</surname><given-names>P.B.</given-names></name><name><surname>Robert</surname><given-names>C.</given-names></name><name><surname>Larkin</surname><given-names>J.</given-names></name><name><surname>Haanen</surname><given-names>J.B.</given-names></name><name><surname>Dummer</surname><given-names>R.</given-names></name><name><surname>Ribas</surname><given-names>A.</given-names></name><name><surname>Hogg</surname><given-names>D.</given-names></name><name><surname>Hamid</surname><given-names>O.</given-names></name><name><surname>Ascierto</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study</article-title><source>Lancet Oncol.</source><year>2014</year><volume>15</volume><fpage>323</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70012-9</pub-id><pub-id pub-id-type="pmid">24508103</pub-id></element-citation></ref><ref id="B12-biomedicines-08-00060"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C.</given-names></name><name><surname>Karaszewska</surname><given-names>B.</given-names></name><name><surname>Schachter</surname><given-names>J.</given-names></name><name><surname>Rutkowski</surname><given-names>P.</given-names></name><name><surname>Mackiewicz</surname><given-names>A.</given-names></name><name><surname>Stroiakovski</surname><given-names>D.</given-names></name><name><surname>Lichinitser</surname><given-names>M.</given-names></name><name><surname>Dummer</surname><given-names>R.</given-names></name><name><surname>Grange</surname><given-names>F.</given-names></name><name><surname>Mortier</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Improved overall survival in melanoma with combined dabrafenib and trametinib</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>30</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1412690</pub-id><?supplied-pmid 25399551?><pub-id pub-id-type="pmid">25399551</pub-id></element-citation></ref><ref id="B13-biomedicines-08-00060"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>G.V.</given-names></name><name><surname>Stroyakovskiy</surname><given-names>D.</given-names></name><name><surname>Gogas</surname><given-names>H.</given-names></name><name><surname>Levchenko</surname><given-names>E.</given-names></name><name><surname>De Braud</surname><given-names>F.</given-names></name><name><surname>Larkin</surname><given-names>J.</given-names></name><name><surname>Garbe</surname><given-names>C.</given-names></name><name><surname>Jouary</surname><given-names>T.</given-names></name><name><surname>Hauschild</surname><given-names>A.</given-names></name><name><surname>Grob</surname><given-names>J.-J.</given-names></name><etal/></person-group><article-title>Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial</article-title><source>Lancet</source><year>2015</year><volume>386</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)60898-4</pub-id><pub-id pub-id-type="pmid">26037941</pub-id></element-citation></ref><ref id="B14-biomedicines-08-00060"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribas</surname><given-names>A.</given-names></name><name><surname>Puzanov</surname><given-names>I.</given-names></name><name><surname>Dummer</surname><given-names>R.</given-names></name><name><surname>Schadendorf</surname><given-names>D.</given-names></name><name><surname>Hamid</surname><given-names>O.</given-names></name><name><surname>Robert</surname><given-names>C.</given-names></name><name><surname>Hodi</surname><given-names>F.S.</given-names></name><name><surname>Schachter</surname><given-names>J.</given-names></name><name><surname>Pavlick</surname><given-names>A.C.</given-names></name><name><surname>Lewis</surname><given-names>K.D.</given-names></name><etal/></person-group><article-title>Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (Keynote-002): A randomised, controlled, phase 2 trial</article-title><source>Lancet Oncol.</source><year>2015</year><volume>16</volume><fpage>908</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00083-2</pub-id><pub-id pub-id-type="pmid">26115796</pub-id></element-citation></ref><ref id="B15-biomedicines-08-00060"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>J.S.</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>S.P.</given-names></name><name><surname>Minor</surname><given-names>D.</given-names></name><name><surname>Hodi</surname><given-names>F.S.</given-names></name><name><surname>Gutzmer</surname><given-names>R.</given-names></name><name><surname>Neyns</surname><given-names>B.</given-names></name><name><surname>Hoeller</surname><given-names>C.</given-names></name><name><surname>Khushalani</surname><given-names>N.I.</given-names></name><name><surname>Miller</surname><given-names>W.H.</given-names></name><name><surname>Lao</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2015</year><volume>16</volume><fpage>375</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)70076-8</pub-id><pub-id pub-id-type="pmid">25795410</pub-id></element-citation></ref><ref id="B16-biomedicines-08-00060"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C.</given-names></name><name><surname>Long</surname><given-names>G.V.</given-names></name><name><surname>Brady</surname><given-names>B.</given-names></name><name><surname>Dutriaux</surname><given-names>C.</given-names></name><name><surname>Maio</surname><given-names>M.</given-names></name><name><surname>Mortier</surname><given-names>L.</given-names></name><name><surname>Hassel</surname><given-names>J.C.</given-names></name><name><surname>Rutkowski</surname><given-names>P.</given-names></name><name><surname>McNeil</surname><given-names>C.</given-names></name><name><surname>Kalinka-Warzocha</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Nivolumab in previously untreated melanoma without <italic>BRAF</italic> mutation</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1412082</pub-id><pub-id pub-id-type="pmid">25399552</pub-id></element-citation></ref><ref id="B17-biomedicines-08-00060"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malas</surname><given-names>S.</given-names></name><name><surname>Harrasser</surname><given-names>M.</given-names></name><name><surname>Lacy</surname><given-names>K.E.</given-names></name><name><surname>Karagiannis</surname><given-names>S.N.</given-names></name></person-group><article-title>Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)</article-title><source>Oncol. Rep.</source><year>2014</year><volume>32</volume><fpage>875</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.3892/or.2014.3275</pub-id><pub-id pub-id-type="pmid">24969320</pub-id></element-citation></ref><ref id="B18-biomedicines-08-00060"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>M.A.</given-names></name><name><surname>Schuchter</surname><given-names>L.M.</given-names></name></person-group><article-title>Chemotherapy for melanoma</article-title><source>Melanoma</source><person-group person-group-type="editor"><name><surname>Kaufman</surname><given-names>H.L.</given-names></name><name><surname>Mehnert</surname><given-names>J.M.</given-names></name></person-group><comment>Cancer Treatment and Research</comment><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2016</year><fpage>209</fpage><lpage>229</lpage><isbn>978-3-319-22539-5</isbn></element-citation></ref><ref id="B19-biomedicines-08-00060"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>C.W.</given-names></name><name><surname>Kovacic</surname><given-names>L.</given-names></name><name><surname>Shah</surname><given-names>A.</given-names></name><name><surname>Klasa</surname><given-names>R.</given-names></name><name><surname>Savage</surname><given-names>K.J.</given-names></name></person-group><article-title>Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide</article-title><source>Oncologist</source><year>2010</year><volume>15</volume><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2009-0237</pub-id><pub-id pub-id-type="pmid">20538743</pub-id></element-citation></ref><ref id="B20-biomedicines-08-00060"><label>20.</label><element-citation publication-type="gov"><article-title>Home&#x02014;ClinicalTrials.gov</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-12-27">(accessed on 27 December 2019)</date-in-citation></element-citation></ref><ref id="B21-biomedicines-08-00060"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testori</surname><given-names>A.</given-names></name><name><surname>Ribero</surname><given-names>S.</given-names></name><name><surname>Bataille</surname><given-names>V.</given-names></name></person-group><article-title>Diagnosis and treatment of in-transit melanoma metastases</article-title><source>Eur. J. Surg. Oncol.</source><year>2017</year><volume>43</volume><fpage>544</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2016.10.005</pub-id><pub-id pub-id-type="pmid">27923593</pub-id></element-citation></ref><ref id="B22-biomedicines-08-00060"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miklav&#x0010d;i&#x0010d;</surname><given-names>D.</given-names></name><name><surname>Ser&#x00161;a</surname><given-names>G.</given-names></name><name><surname>Brecelj</surname><given-names>E.</given-names></name><name><surname>Gehl</surname><given-names>J.</given-names></name><name><surname>Soden</surname><given-names>D.</given-names></name><name><surname>Bianchi</surname><given-names>G.</given-names></name><name><surname>Ruggieri</surname><given-names>P.</given-names></name><name><surname>Rossi</surname><given-names>C.R.</given-names></name><name><surname>Campana</surname><given-names>L.G.</given-names></name><name><surname>Jarm</surname><given-names>T.</given-names></name></person-group><article-title>Electrochemotherapy: Technological advancements for efficient electroporation-based treatment of internal tumors</article-title><source>Med. Biol. Eng. Comput.</source><year>2012</year><volume>50</volume><fpage>1213</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1007/s11517-012-0991-8</pub-id><pub-id pub-id-type="pmid">23179413</pub-id></element-citation></ref><ref id="B23-biomedicines-08-00060"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthiessen</surname><given-names>L.W.</given-names></name><name><surname>Chalmers</surname><given-names>R.L.</given-names></name><name><surname>Sainsbury</surname><given-names>D.C.G.</given-names></name><name><surname>Veeramani</surname><given-names>S.</given-names></name><name><surname>Kessell</surname><given-names>G.</given-names></name><name><surname>Humphreys</surname><given-names>A.C.</given-names></name><name><surname>Bond</surname><given-names>J.E.</given-names></name><name><surname>Muir</surname><given-names>T.</given-names></name><name><surname>Gehl</surname><given-names>J.</given-names></name></person-group><article-title>Management of cutaneous metastases using electrochemotherapy</article-title><source>Acta Oncol.</source><year>2011</year><volume>50</volume><fpage>621</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.3109/0284186X.2011.573626</pub-id><pub-id pub-id-type="pmid">21574833</pub-id></element-citation></ref><ref id="B24-biomedicines-08-00060"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>E.</given-names></name><name><surname>Mamalis</surname><given-names>A.</given-names></name><name><surname>Ho</surname><given-names>D.</given-names></name><name><surname>Jagdeo</surname><given-names>J.</given-names></name></person-group><article-title>Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: A systematic review</article-title><source>Arch. Dermatol. Res.</source><year>2017</year><volume>309</volume><fpage>229</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1007/s00403-017-1720-9</pub-id><?supplied-pmid 28314913?><pub-id pub-id-type="pmid">28314913</pub-id></element-citation></ref><ref id="B25-biomedicines-08-00060"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>Y.-Y.</given-names></name><name><surname>Huang</surname><given-names>H.-C.</given-names></name><name><surname>Avci</surname><given-names>P.</given-names></name><name><surname>Chiang</surname><given-names>L.Y.</given-names></name><name><surname>Hamblin</surname><given-names>M.R.</given-names></name></person-group><article-title>Photodynamic therapy with decacationic [60]fullerene monoadducts: Effect of a light absorbing electron-donor antenna and micellar formulation</article-title><source>Nanomedicine</source><year>2014</year><volume>10</volume><fpage>795</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2013.11.014</pub-id><?supplied-pmid 24333585?><pub-id pub-id-type="pmid">24333585</pub-id></element-citation></ref><ref id="B26-biomedicines-08-00060"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougherty</surname><given-names>T.J.</given-names></name><name><surname>Gomer</surname><given-names>C.J.</given-names></name><name><surname>Henderson</surname><given-names>B.W.</given-names></name><name><surname>Jori</surname><given-names>G.</given-names></name><name><surname>Kessel</surname><given-names>D.</given-names></name><name><surname>Korbelik</surname><given-names>M.</given-names></name><name><surname>Moan</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>Q.</given-names></name></person-group><article-title>Photodynamic therapy</article-title><source>J. Natl. Cancer Inst.</source><year>1998</year><volume>90</volume><fpage>889</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1093/jnci/90.12.889</pub-id><?supplied-pmid 9637138?><pub-id pub-id-type="pmid">9637138</pub-id></element-citation></ref><ref id="B27-biomedicines-08-00060"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>S.B.</given-names></name><name><surname>Brown</surname><given-names>E.A.</given-names></name><name><surname>Walker</surname><given-names>I.</given-names></name></person-group><article-title>The present and future role of photodynamic therapy in cancer treatment</article-title><source>Lancet Oncol.</source><year>2004</year><volume>5</volume><fpage>497</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(04)01529-3</pub-id><pub-id pub-id-type="pmid">15288239</pub-id></element-citation></ref><ref id="B28-biomedicines-08-00060"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longo</surname><given-names>J.</given-names></name><name><surname>Muehlmann</surname><given-names>L.</given-names></name><name><surname>Almeida-Santos</surname><given-names>M.</given-names></name><name><surname>Azevedo</surname><given-names>R.</given-names></name></person-group><article-title>Preventing metastasis by targeting lymphatic vessels with photodynamic therapy based on nanostructured photosensitizers</article-title><source>J. Nanomed. Nanotechnol.</source><year>2015</year><volume>6</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.4172/2157-7439.1000318</pub-id></element-citation></ref><ref id="B29-biomedicines-08-00060"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldea</surname><given-names>I.</given-names></name><name><surname>Filip</surname><given-names>A.G.</given-names></name></person-group><article-title>Photodynamic therapy in melanoma&#x02014;An update</article-title><source>J. Physiol. Pharmacol.</source><year>2012</year><volume>63</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">22653896</pub-id></element-citation></ref><ref id="B30-biomedicines-08-00060"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.-Y.</given-names></name><name><surname>Vecchio</surname><given-names>D.</given-names></name><name><surname>Avci</surname><given-names>P.</given-names></name><name><surname>Yin</surname><given-names>R.</given-names></name><name><surname>Garcia-Diaz</surname><given-names>M.</given-names></name><name><surname>Hamblin</surname><given-names>M.R.</given-names></name></person-group><article-title>Melanoma resistance to photodynamic therapy: New insights</article-title><source>Biol. Chem.</source><year>2013</year><volume>394</volume><fpage>239</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1515/hsz-2012-0228</pub-id><pub-id pub-id-type="pmid">23152406</pub-id></element-citation></ref><ref id="B31-biomedicines-08-00060"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biteghe</surname><given-names>F.N.</given-names></name><name><surname>Davids</surname><given-names>L.</given-names></name></person-group><article-title>A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells</article-title><source>J. Photochem. Photobiol. B Biol.</source><year>2017</year><volume>166</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jphotobiol.2016.11.004</pub-id></element-citation></ref><ref id="B32-biomedicines-08-00060"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>Oncolytic alphaviruses in cancer immunotherapy</article-title><source>Vaccines (Basel)</source><year>2017</year><volume>5</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines5020009</pub-id></element-citation></ref><ref id="B33-biomedicines-08-00060"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>D.</given-names></name></person-group><article-title>Novel viral vector systems for gene therapy</article-title><source>Viruses</source><year>2010</year><volume>2</volume><fpage>1002</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.3390/v2041002</pub-id><?supplied-pmid 21994667?><pub-id pub-id-type="pmid">21994667</pub-id></element-citation></ref><ref id="B34-biomedicines-08-00060"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>M.K.</given-names></name><name><surname>Rill</surname><given-names>D.R.</given-names></name><name><surname>Krance</surname><given-names>R.A.</given-names></name><name><surname>Ihle</surname><given-names>J.N.</given-names></name><name><surname>Moen</surname><given-names>R.C.</given-names></name><name><surname>Mirro</surname><given-names>J.</given-names></name><name><surname>Anderson</surname><given-names>W.F.</given-names></name></person-group><article-title>Gene-marking to trace origin of relapse after autologous bone-marrow transplantation</article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>85</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)92560-G</pub-id><pub-id pub-id-type="pmid">8093407</pub-id></element-citation></ref><ref id="B35-biomedicines-08-00060"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conry</surname><given-names>R.M.</given-names></name><name><surname>Westbrook</surname><given-names>B.</given-names></name><name><surname>McKee</surname><given-names>S.</given-names></name><name><surname>Norwood</surname><given-names>T.G.</given-names></name></person-group><article-title>Talimogene laherparepvec: First in class oncolytic virotherapy</article-title><source>Hum. Vaccin. Immunother.</source><year>2018</year><volume>14</volume><fpage>839</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1412896</pub-id><?supplied-pmid 29420123?><pub-id pub-id-type="pmid">29420123</pub-id></element-citation></ref><ref id="B36-biomedicines-08-00060"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>Viral vectors in gene therapy</article-title><source>Diseases</source><year>2018</year><volume>6</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.3390/diseases6020042</pub-id></element-citation></ref><ref id="B37-biomedicines-08-00060"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiedner</surname><given-names>G.</given-names></name><name><surname>Morral</surname><given-names>N.</given-names></name><name><surname>Parks</surname><given-names>R.J.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Koopmans</surname><given-names>S.C.</given-names></name><name><surname>Langston</surname><given-names>C.</given-names></name><name><surname>Graham</surname><given-names>F.L.</given-names></name><name><surname>Beaudet</surname><given-names>A.L.</given-names></name><name><surname>Kochanek</surname><given-names>S.</given-names></name></person-group><article-title>Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity</article-title><source>Nat. Genet.</source><year>1998</year><volume>18</volume><fpage>180</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/ng0298-180</pub-id><pub-id pub-id-type="pmid">9462752</pub-id></element-citation></ref><ref id="B38-biomedicines-08-00060"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Tian</surname><given-names>H.</given-names></name><name><surname>Qi</surname><given-names>M.</given-names></name><name><surname>Zhai</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Fu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice</article-title><source>Curr. Gene Ther.</source><year>2012</year><volume>12</volume><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.2174/156652312800099599</pub-id><pub-id pub-id-type="pmid">22384806</pub-id></element-citation></ref><ref id="B39-biomedicines-08-00060"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>B.K.</given-names></name><name><surname>Dong</surname><given-names>B.</given-names></name><name><surname>Nguyen</surname><given-names>C.T.</given-names></name><name><surname>Polyakova</surname><given-names>I.</given-names></name><name><surname>Silverman</surname><given-names>R.H.</given-names></name></person-group><article-title>Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy</article-title><source>Mol. Ther.</source><year>2013</year><volume>21</volume><fpage>1749</fpage><lpage>1757</lpage><pub-id pub-id-type="doi">10.1038/mt.2013.112</pub-id><pub-id pub-id-type="pmid">23732991</pub-id></element-citation></ref><ref id="B40-biomedicines-08-00060"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname><given-names>S.</given-names></name><name><surname>Shapira</surname><given-names>A.</given-names></name><name><surname>Kazanov</surname><given-names>D.</given-names></name><name><surname>Hevroni</surname><given-names>G.</given-names></name><name><surname>Kraus</surname><given-names>S.</given-names></name><name><surname>Arber</surname><given-names>N.</given-names></name></person-group><article-title>Selective eradication of cancer cells by delivery of adenovirus-based toxins</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>38581</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.16934</pub-id><pub-id pub-id-type="pmid">28445136</pub-id></element-citation></ref><ref id="B41-biomedicines-08-00060"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato-Dahlman</surname><given-names>M.</given-names></name><name><surname>Miura</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>J.L.</given-names></name><name><surname>Hajeri</surname><given-names>P.</given-names></name><name><surname>Jacobsen</surname><given-names>K.</given-names></name><name><surname>Davydova</surname><given-names>J.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name></person-group><article-title>CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>76044</fpage><lpage>76056</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18340</pub-id><pub-id pub-id-type="pmid">29100290</pub-id></element-citation></ref><ref id="B42-biomedicines-08-00060"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>T.</given-names></name></person-group><article-title>A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer</article-title><source>Acta Med. Okayama</source><year>2011</year><volume>65</volume><fpage>151</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">21709712</pub-id></element-citation></ref><ref id="B43-biomedicines-08-00060"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.-F.</given-names></name><name><surname>Zhang</surname><given-names>B.-C.</given-names></name><name><surname>Zhang</surname><given-names>A.-R.</given-names></name><name><surname>Wu</surname><given-names>T.-T.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>L.-F.</given-names></name><name><surname>Wang</surname><given-names>W.-X.</given-names></name><name><surname>Gao</surname><given-names>J.-F.</given-names></name><name><surname>Fang</surname><given-names>D.-C.</given-names></name><name><surname>Rao</surname><given-names>Z.-G.</given-names></name></person-group><article-title>Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer</article-title><source>Oncol. Rep.</source><year>2013</year><volume>30</volume><fpage>1989</fpage><lpage>1995</lpage><pub-id pub-id-type="doi">10.3892/or.2013.2663</pub-id><?supplied-pmid 23933826?><pub-id pub-id-type="pmid">23933826</pub-id></element-citation></ref><ref id="B44-biomedicines-08-00060"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>P.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Ni</surname><given-names>A.</given-names></name><name><surname>Chu</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.-Y.</given-names></name><name><surname>Duan</surname><given-names>Y.</given-names></name></person-group><article-title>Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><fpage>11548</fpage><lpage>11560</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b06182</pub-id><?supplied-pmid 27977128?><pub-id pub-id-type="pmid">27977128</pub-id></element-citation></ref><ref id="B45-biomedicines-08-00060"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Xiao</surname><given-names>F.</given-names></name><name><surname>Bai</surname><given-names>Z.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><etal/></person-group><article-title>An oncolytic adenovirus encoding decorin and granulocyte macrophage colony stimulating factor inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune activation</article-title><source>Hum. Gene Ther.</source><year>2017</year><volume>28</volume><fpage>667</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1089/hum.2017.033</pub-id><?supplied-pmid 28530155?><pub-id pub-id-type="pmid">28530155</pub-id></element-citation></ref><ref id="B46-biomedicines-08-00060"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samulski</surname><given-names>R.J.</given-names></name><name><surname>Muzyczka</surname><given-names>N.</given-names></name></person-group><article-title>AAV-mediated gene therapy for research and therapeutic purposes</article-title><source>Ann. Rev. Virol.</source><year>2014</year><volume>1</volume><fpage>427</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-031413-085355</pub-id><?supplied-pmid 26958729?><pub-id pub-id-type="pmid">26958729</pub-id></element-citation></ref><ref id="B47-biomedicines-08-00060"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K.</given-names></name><name><surname>Kim</surname><given-names>W.-J.</given-names></name><name><surname>Cho</surname><given-names>Y.-H.</given-names></name><name><surname>Lee</surname><given-names>Y.-I.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Jeong</surname><given-names>S.</given-names></name><name><surname>Cho</surname><given-names>E.-S.</given-names></name><name><surname>Chang</surname><given-names>S.-I.</given-names></name><name><surname>Moon</surname><given-names>S.-K.</given-names></name><name><surname>Kang</surname><given-names>B.-S.</given-names></name><etal/></person-group><article-title>Cancer gene therapy using adeno-associated virus vectors</article-title><source>Front. Biosci.</source><year>2008</year><volume>13</volume><fpage>2653</fpage><lpage>2659</lpage><pub-id pub-id-type="doi">10.2741/2872</pub-id><pub-id pub-id-type="pmid">17981740</pub-id></element-citation></ref><ref id="B48-biomedicines-08-00060"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mingozzi</surname><given-names>F.</given-names></name><name><surname>High</surname><given-names>K.A.</given-names></name></person-group><article-title>Immune responses to AAV vectors: Overcoming barriers to successful gene therapy</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-01-306647</pub-id><pub-id pub-id-type="pmid">23596044</pub-id></element-citation></ref><ref id="B49-biomedicines-08-00060"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grieger</surname><given-names>J.C.</given-names></name><name><surname>Samulski</surname><given-names>R.J.</given-names></name></person-group><article-title>Packaging capacity of adeno-associated virus serotypes: Impact of larger genomes on infectivity and postentry steps</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>9933</fpage><lpage>9944</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.15.9933-9944.2005</pub-id><pub-id pub-id-type="pmid">16014954</pub-id></element-citation></ref><ref id="B50-biomedicines-08-00060"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crommentuijn</surname><given-names>M.H.</given-names></name><name><surname>Kantar</surname><given-names>R.</given-names></name><name><surname>Noske</surname><given-names>D.P.</given-names></name><name><surname>Vandertop</surname><given-names>W.P.</given-names></name><name><surname>Badr</surname><given-names>C.E.</given-names></name><name><surname>W&#x000fc;rdinger</surname><given-names>T.</given-names></name><name><surname>Maguire</surname><given-names>C.A.</given-names></name><name><surname>Tannous</surname><given-names>B.A.</given-names></name></person-group><article-title>Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model</article-title><source>Mol. Ther. Oncol.</source><year>2016</year><volume>3</volume><fpage>16017</fpage><pub-id pub-id-type="doi">10.1038/mto.2016.17</pub-id></element-citation></ref><ref id="B51-biomedicines-08-00060"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steel</surname><given-names>J.C.</given-names></name><name><surname>Di Pasquale</surname><given-names>G.</given-names></name><name><surname>Ramlogan</surname><given-names>C.A.</given-names></name><name><surname>Patel</surname><given-names>V.</given-names></name><name><surname>Chiorini</surname><given-names>J.A.</given-names></name><name><surname>Morris</surname><given-names>J.C.</given-names></name></person-group><article-title>Oral vaccination with adeno-associated virus vectors expressing the neu oncogene inhibits the growth of murine breast cancer</article-title><source>Mol. Ther.</source><year>2013</year><volume>21</volume><fpage>680</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.260</pub-id><pub-id pub-id-type="pmid">23295951</pub-id></element-citation></ref><ref id="B52-biomedicines-08-00060"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma</article-title><source>Tumour Biol.</source><year>2013</year><volume>34</volume><fpage>3027</fpage><lpage>3034</lpage><pub-id pub-id-type="doi">10.1007/s13277-013-0867-z</pub-id><pub-id pub-id-type="pmid">23907578</pub-id></element-citation></ref><ref id="B53-biomedicines-08-00060"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>H.</given-names></name><name><surname>Chang</surname><given-names>J.C.</given-names></name><name><surname>Xu</surname><given-names>S.M.</given-names></name><name><surname>Kan</surname><given-names>Y.W.</given-names></name></person-group><article-title>Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene</article-title><source>Hum. Gene Ther.</source><year>1996</year><volume>7</volume><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1089/hum.1996.7.4-463</pub-id><?supplied-pmid 8800740?><pub-id pub-id-type="pmid">8800740</pub-id></element-citation></ref><ref id="B54-biomedicines-08-00060"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>S.-T.</given-names></name><name><surname>Shi</surname><given-names>H.S.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>H.L.</given-names></name><name><surname>He</surname><given-names>S.S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name></person-group><article-title>AAV2-mediated gene transfer of VEGF-Trap with potent suppression of primary breast tumor growth and spontaneous pulmonary metastases by long-term expression</article-title><source>Oncol. Rep.</source><year>2012</year><volume>28</volume><fpage>1332</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.3892/or.2012.1915</pub-id><?supplied-pmid 22824831?><pub-id pub-id-type="pmid">22824831</pub-id></element-citation></ref><ref id="B55-biomedicines-08-00060"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>A.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Terranova</surname><given-names>P.F.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Thrasher</surname><given-names>J.B.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name></person-group><article-title>Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: A preclinical study</article-title><source>Int. J. Cancer</source><year>2010</year><volume>126</volume><fpage>764</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1002/ijc.24778</pub-id><?supplied-pmid 19642108?><pub-id pub-id-type="pmid">19642108</pub-id></element-citation></ref><ref id="B56-biomedicines-08-00060"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>C.-S.</given-names></name><name><surname>Laurie</surname><given-names>N.</given-names></name><name><surname>Holzmacher</surname><given-names>J.</given-names></name><name><surname>Spence</surname><given-names>Y.</given-names></name><name><surname>Nathwani</surname><given-names>A.C.</given-names></name><name><surname>Davidoff</surname><given-names>A.M.</given-names></name><name><surname>Dyer</surname><given-names>M.A.</given-names></name></person-group><article-title>AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models</article-title><source>Neuromol. Med.</source><year>2009</year><volume>11</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s12017-009-8059-0</pub-id><?supplied-pmid 19306089?><pub-id pub-id-type="pmid">19306089</pub-id></element-citation></ref><ref id="B57-biomedicines-08-00060"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heikkil&#x000e4;</surname><given-names>J.E.</given-names></name><name><surname>V&#x000e4;h&#x000e4;-Koskela</surname><given-names>M.J.</given-names></name><name><surname>Ruotsalainen</surname><given-names>J.J.</given-names></name><name><surname>Martikainen</surname><given-names>M.W.</given-names></name><name><surname>Stanford</surname><given-names>M.M.</given-names></name><name><surname>McCart</surname><given-names>J.A.</given-names></name><name><surname>Bell</surname><given-names>J.C.</given-names></name><name><surname>Hinkkanen</surname><given-names>A.E.</given-names></name></person-group><article-title>Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e8603</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0008603</pub-id><?supplied-pmid 20066051?><pub-id pub-id-type="pmid">20066051</pub-id></element-citation></ref><ref id="B58-biomedicines-08-00060"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>H.</given-names></name><name><surname>Zaks</surname><given-names>T.Z.</given-names></name><name><surname>Wang</surname><given-names>R.-F.</given-names></name><name><surname>Irvine</surname><given-names>K.R.</given-names></name><name><surname>Kammula</surname><given-names>U.S.</given-names></name><name><surname>Marincola</surname><given-names>F.M.</given-names></name><name><surname>Leitner</surname><given-names>W.W.</given-names></name><name><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>Cancer therapy using a self-replicating RNA vaccine</article-title><source>Nat. Med.</source><year>1999</year><volume>5</volume><fpage>823</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1038/10548</pub-id><?supplied-pmid 10395329?><pub-id pub-id-type="pmid">10395329</pub-id></element-citation></ref><ref id="B59-biomedicines-08-00060"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>A.-M.</given-names></name><name><surname>Morris-Downes</surname><given-names>M.M.</given-names></name><name><surname>Sheahan</surname><given-names>B.J.</given-names></name><name><surname>Atkins</surname><given-names>G.J.</given-names></name></person-group><article-title>Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles</article-title><source>Gene Ther.</source><year>2000</year><volume>7</volume><fpage>1477</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301263</pub-id><pub-id pub-id-type="pmid">11001367</pub-id></element-citation></ref><ref id="B60-biomedicines-08-00060"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x000e4;h&#x000e4;-Koskela</surname><given-names>M.J.V.</given-names></name><name><surname>Kallio</surname><given-names>J.P.</given-names></name><name><surname>Jansson</surname><given-names>L.C.</given-names></name><name><surname>Heikkil&#x000e4;</surname><given-names>J.E.</given-names></name><name><surname>Zakhartchenko</surname><given-names>V.A.</given-names></name><name><surname>Kallajoki</surname><given-names>M.A.</given-names></name><name><surname>K&#x000e4;h&#x000e4;ri</surname><given-names>V.-M.</given-names></name><name><surname>Hinkkanen</surname><given-names>A.E.</given-names></name></person-group><article-title>Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>7185</fpage><lpage>7194</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2214</pub-id><pub-id pub-id-type="pmid">16849565</pub-id></element-citation></ref><ref id="B61-biomedicines-08-00060"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e4;&#x000e4;tt&#x000e4;</surname><given-names>A.M.</given-names></name><name><surname>Liimatainen</surname><given-names>T.</given-names></name><name><surname>Wahlfors</surname><given-names>T.</given-names></name><name><surname>Wirth</surname><given-names>T.</given-names></name><name><surname>V&#x000e4;h&#x000e4;-Koskela</surname><given-names>M.</given-names></name><name><surname>Jansson</surname><given-names>L.</given-names></name><name><surname>Valonen</surname><given-names>P.</given-names></name><name><surname>H&#x000e4;kkinen</surname><given-names>K.</given-names></name><name><surname>Rautsi</surname><given-names>O.</given-names></name><name><surname>Pellinen</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models</article-title><source>Int. J. Cancer</source><year>2007</year><volume>121</volume><fpage>863</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1002/ijc.22758</pub-id><pub-id pub-id-type="pmid">17443493</pub-id></element-citation></ref><ref id="B62-biomedicines-08-00060"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ketola</surname><given-names>A.</given-names></name><name><surname>Hinkkanen</surname><given-names>A.</given-names></name><name><surname>Yongabi</surname><given-names>F.</given-names></name><name><surname>Furu</surname><given-names>P.</given-names></name><name><surname>M&#x000e4;&#x000e4;tt&#x000e4;</surname><given-names>A.-M.</given-names></name><name><surname>Liimatainen</surname><given-names>T.</given-names></name><name><surname>Pirinen</surname><given-names>R.</given-names></name><name><surname>Bj&#x000f6;rn</surname><given-names>M.</given-names></name><name><surname>Hakkarainen</surname><given-names>T.</given-names></name><name><surname>M&#x000e4;kinen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>8342</fpage><lpage>8350</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0251</pub-id><pub-id pub-id-type="pmid">18922906</pub-id></element-citation></ref><ref id="B63-biomedicines-08-00060"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venticinque</surname><given-names>L.</given-names></name><name><surname>Meruelo</surname><given-names>D.</given-names></name></person-group><article-title>Sindbis viral vector induced apoptosis requires translational inhibition and signaling through Mcl-1 and Bak</article-title><source>Mol. Cancer</source><year>2010</year><volume>9</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-9-37</pub-id><?supplied-pmid 20152035?><pub-id pub-id-type="pmid">20152035</pub-id></element-citation></ref><ref id="B64-biomedicines-08-00060"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martikainen</surname><given-names>M.</given-names></name><name><surname>Ruotsalainen</surname><given-names>J.</given-names></name><name><surname>Tuomela</surname><given-names>J.</given-names></name><name><surname>H&#x000e4;rk&#x000f6;nen</surname><given-names>P.</given-names></name><name><surname>Essand</surname><given-names>M.</given-names></name><name><surname>Heikkil&#x000e4;</surname><given-names>J.</given-names></name><name><surname>Hinkkanen</surname><given-names>A.</given-names></name></person-group><article-title>Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotypic human prostate tumours in mice</article-title><source>Br. J. Cancer</source><year>2017</year><volume>117</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.151</pub-id><?supplied-pmid 28557974?><pub-id pub-id-type="pmid">28557974</pub-id></element-citation></ref><ref id="B65-biomedicines-08-00060"><label>65.</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>A.L.</given-names></name><name><surname>Marconi</surname><given-names>P.</given-names></name><name><surname>Argnani</surname><given-names>R.</given-names></name><name><surname>Manservigi</surname><given-names>R.</given-names></name></person-group><article-title>HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.eurekaselect.com/61113/article">http://www.eurekaselect.com/61113/article</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-11-12">(accessed on 12 November 2019)</date-in-citation></element-citation></ref><ref id="B66-biomedicines-08-00060"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>K.D.</given-names></name><name><surname>Cassam</surname><given-names>A.K.</given-names></name><name><surname>Chan</surname><given-names>B.</given-names></name><name><surname>Peters</surname><given-names>A.A.</given-names></name><name><surname>Weaver</surname><given-names>L.C.</given-names></name><name><surname>Dekaban</surname><given-names>G.A.</given-names></name></person-group><article-title>A multi-mutant herpes simplex virus vector has minimal cytotoxic effects on the distribution of filamentous actin, alpha-actinin 2 and a glutamate receptor in differentiated PC12 cells</article-title><source>J. Neurovirol.</source><year>2000</year><volume>6</volume><fpage>33</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.3109/13550280009006380</pub-id><?supplied-pmid 10786995?><pub-id pub-id-type="pmid">10786995</pub-id></element-citation></ref><ref id="B67-biomedicines-08-00060"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delwar</surname><given-names>Z.M.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Kuo</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>Bu</surname><given-names>L.</given-names></name><name><surname>Rennie</surname><given-names>P.S.</given-names></name><name><surname>Jia</surname><given-names>W.W.</given-names></name></person-group><article-title>Tumour-specific triple-regulated oncolytic herpes virus to target glioma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>28658</fpage><lpage>28669</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8637</pub-id><pub-id pub-id-type="pmid">27070093</pub-id></element-citation></ref><ref id="B68-biomedicines-08-00060"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esaki</surname><given-names>S.</given-names></name><name><surname>Rabkin</surname><given-names>S.D.</given-names></name><name><surname>Martuza</surname><given-names>R.L.</given-names></name><name><surname>Wakimoto</surname><given-names>H.</given-names></name></person-group><article-title>Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma</article-title><source>Am. J. Cancer Res.</source><year>2016</year><volume>6</volume><fpage>300</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">27186404</pub-id></element-citation></ref><ref id="B69-biomedicines-08-00060"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhen</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name></person-group><article-title>Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo</article-title><source>Ther. Clin. Risk Manag.</source><year>2017</year><volume>13</volume><fpage>117</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.2147/TCRM.S128575</pub-id><pub-id pub-id-type="pmid">28223815</pub-id></element-citation></ref><ref id="B70-biomedicines-08-00060"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Nakashima</surname><given-names>H.</given-names></name><name><surname>Decklever</surname><given-names>T.D.</given-names></name><name><surname>Nace</surname><given-names>R.A.</given-names></name><name><surname>Russell</surname><given-names>S.J.</given-names></name></person-group><article-title>HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy</article-title><source>Cancer Gene Ther.</source><year>2013</year><volume>20</volume><fpage>478</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/cgt.2013.43</pub-id><pub-id pub-id-type="pmid">23868101</pub-id></element-citation></ref><ref id="B71-biomedicines-08-00060"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.-Y.</given-names></name><name><surname>Wang</surname><given-names>P.-Y.</given-names></name><name><surname>Hutzen</surname><given-names>B.</given-names></name><name><surname>Sprague</surname><given-names>L.</given-names></name><name><surname>Swain</surname><given-names>H.M.</given-names></name><name><surname>Love</surname><given-names>J.K.</given-names></name><name><surname>Stanek</surname><given-names>J.R.</given-names></name><name><surname>Boon</surname><given-names>L.</given-names></name><name><surname>Conner</surname><given-names>J.</given-names></name><name><surname>Cripe</surname><given-names>T.P.</given-names></name></person-group><article-title>Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>2396</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-02503-8</pub-id><pub-id pub-id-type="pmid">28539588</pub-id></element-citation></ref><ref id="B72-biomedicines-08-00060"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meshii</surname><given-names>N.</given-names></name><name><surname>Takahashi</surname><given-names>G.</given-names></name><name><surname>Okunaga</surname><given-names>S.</given-names></name><name><surname>Hamada</surname><given-names>M.</given-names></name><name><surname>Iwai</surname><given-names>S.</given-names></name><name><surname>Takasu</surname><given-names>A.</given-names></name><name><surname>Ogawa</surname><given-names>Y.</given-names></name><name><surname>Yura</surname><given-names>Y.</given-names></name></person-group><article-title>Enhancement of systemic tumor immunity for squamous cell carcinoma cells by an oncolytic herpes simplex virus</article-title><source>Cancer Gene Ther.</source><year>2013</year><volume>20</volume><fpage>493</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/cgt.2013.45</pub-id><pub-id pub-id-type="pmid">23887644</pub-id></element-citation></ref><ref id="B73-biomedicines-08-00060"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galanis</surname><given-names>E.</given-names></name><name><surname>Markovic</surname><given-names>S.N.</given-names></name><name><surname>Suman</surname><given-names>V.J.</given-names></name><name><surname>Nuovo</surname><given-names>G.J.</given-names></name><name><surname>Vile</surname><given-names>R.G.</given-names></name><name><surname>Kottke</surname><given-names>T.J.</given-names></name><name><surname>Nevala</surname><given-names>W.K.</given-names></name><name><surname>Thompson</surname><given-names>M.A.</given-names></name><name><surname>Lewis</surname><given-names>J.E.</given-names></name><name><surname>Rumilla</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Phase II trial of intravenous administration of Reolysin<sup>&#x000ae;</sup> (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma</article-title><source>Mol. Ther.</source><year>2012</year><volume>20</volume><fpage>1998</fpage><pub-id pub-id-type="doi">10.1038/mt.2012.146</pub-id><pub-id pub-id-type="pmid">22871663</pub-id></element-citation></ref><ref id="B74-biomedicines-08-00060"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schambach</surname><given-names>A.</given-names></name><name><surname>Morgan</surname><given-names>M.</given-names></name></person-group><article-title>Retroviral vectors for cancer gene therapy</article-title><source>Recent Results Cancer Res.</source><year>2016</year><volume>209</volume><fpage>17</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">28101685</pub-id></element-citation></ref><ref id="B75-biomedicines-08-00060"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W.S.</given-names></name><name><surname>Pathak</surname><given-names>V.K.</given-names></name></person-group><article-title>Design of retroviral vectors and helper cells for gene therapy</article-title><source>Pharmacol. Rev.</source><year>2000</year><volume>52</volume><fpage>493</fpage><lpage>511</lpage><?supplied-pmid 11121508?><pub-id pub-id-type="pmid">11121508</pub-id></element-citation></ref><ref id="B76-biomedicines-08-00060"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanden Driessche</surname><given-names>T.</given-names></name><name><surname>Naldini</surname><given-names>L.</given-names></name><name><surname>Collen</surname><given-names>D.</given-names></name><name><surname>Chuah</surname><given-names>M.K.</given-names></name></person-group><article-title>Oncoretroviral and lentiviral vector-mediated gene therapy</article-title><source>Methods Enzymol.</source><year>2002</year><volume>346</volume><fpage>573</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">11883092</pub-id></element-citation></ref><ref id="B77-biomedicines-08-00060"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T.T.</given-names></name><name><surname>Parab</surname><given-names>S.</given-names></name><name><surname>Burnett</surname><given-names>R.</given-names></name><name><surname>Diago</surname><given-names>O.</given-names></name><name><surname>Ostertag</surname><given-names>D.</given-names></name><name><surname>Hofman</surname><given-names>F.M.</given-names></name><name><surname>Espinoza</surname><given-names>F.L.</given-names></name><name><surname>Martin</surname><given-names>B.</given-names></name><name><surname>Iba&#x000f1;ez</surname><given-names>C.E.</given-names></name><name><surname>Kasahara</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model</article-title><source>Hum. Gene Ther.</source><year>2015</year><volume>26</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1089/hum.2014.100</pub-id><?supplied-pmid 25419577?><pub-id pub-id-type="pmid">25419577</pub-id></element-citation></ref><ref id="B78-biomedicines-08-00060"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakimoto</surname><given-names>H.</given-names></name><name><surname>Yoshida</surname><given-names>Y.</given-names></name><name><surname>Ayoyagi</surname><given-names>M.</given-names></name><name><surname>Hirakawa</surname><given-names>K.</given-names></name><name><surname>Hamada</surname><given-names>H.</given-names></name></person-group><article-title>Efficient retrovirus-mediated cytokine-gene transduction of primary-cultured human glioma cells for tumor vaccination therapy</article-title><source>Jpn. J. Cancer Res.</source><year>1997</year><volume>88</volume><fpage>296</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.1997.tb00381.x</pub-id><pub-id pub-id-type="pmid">9140115</pub-id></element-citation></ref><ref id="B79-biomedicines-08-00060"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigna</surname><given-names>E.</given-names></name><name><surname>Naldini</surname><given-names>L.</given-names></name></person-group><article-title>Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy</article-title><source>J. Gene Med.</source><year>2000</year><volume>2</volume><fpage>308</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1002/1521-2254(200009/10)2:5&#x0003c;308::AID-JGM131&#x0003e;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">11045424</pub-id></element-citation></ref><ref id="B80-biomedicines-08-00060"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>M.A.</given-names></name><name><surname>Glorioso</surname><given-names>J.C.</given-names></name><name><surname>Naldini</surname><given-names>L.</given-names></name></person-group><article-title>Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics</article-title><source>Nat. Med.</source><year>2001</year><volume>7</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/83324</pub-id><pub-id pub-id-type="pmid">11135613</pub-id></element-citation></ref><ref id="B81-biomedicines-08-00060"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>T.</given-names></name><name><surname>Dai</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>I.</given-names></name></person-group><article-title>Lentivirus-mediated knockdown of CEP55 suppressed cell proliferation of breast cancer cells</article-title><source>Biosc. Trends</source><year>2016</year><volume>10</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.5582/bst.2016.01010</pub-id></element-citation></ref><ref id="B82-biomedicines-08-00060"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>H.-Q.</given-names></name><name><surname>Xi</surname><given-names>H.-L.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Qin</surname><given-names>R.-H.</given-names></name></person-group><article-title>Inhibition of CDH17 gene expression via RNA interference reduces proliferation and apoptosis of human MKN28 gastric cancer cells</article-title><source>Int. J. Oncol.</source><year>2017</year><volume>50</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3892/ijo.2016.3783</pub-id><pub-id pub-id-type="pmid">27909714</pub-id></element-citation></ref><ref id="B83-biomedicines-08-00060"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Z.Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Haung</surname><given-names>G.</given-names></name><name><surname>Yin</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>W.P.</given-names></name></person-group><article-title>Lentivirus-mediated TDP52L2 depletion inhibits the proliferation of liver cancer cells in vitro</article-title><source>Int. J. Clin. Exp. Med.</source><year>2015</year><volume>8</volume><fpage>233</fpage><lpage>241</lpage></element-citation></ref><ref id="B84-biomedicines-08-00060"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravet</surname><given-names>E.</given-names></name><name><surname>Lulka</surname><given-names>H.</given-names></name><name><surname>Gross</surname><given-names>F.</given-names></name><name><surname>Casteilla</surname><given-names>L.</given-names></name><name><surname>Buscail</surname><given-names>L.</given-names></name><name><surname>Cordelier</surname><given-names>P.</given-names></name></person-group><article-title>Using lentiviral vectors for efficient pancreatic cancer gene therapy</article-title><source>Cancer Gene Ther.</source><year>2010</year><volume>17</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/cgt.2009.79</pub-id><?supplied-pmid 19911032?><pub-id pub-id-type="pmid">19911032</pub-id></element-citation></ref><ref id="B85-biomedicines-08-00060"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>G.-H.</given-names></name><name><surname>Chen</surname><given-names>B.-A.</given-names></name></person-group><article-title>RNAi-mediated knockdown of MCM7 gene on CML cells and its therapeutic potential for leukemia</article-title><source>Med. Oncol.</source><year>2017</year><volume>34</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1007/s12032-016-0878-x</pub-id><?supplied-pmid 28058629?><pub-id pub-id-type="pmid">28058629</pub-id></element-citation></ref><ref id="B86-biomedicines-08-00060"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osakada</surname><given-names>F.</given-names></name><name><surname>Callaway</surname><given-names>E.M.</given-names></name></person-group><article-title>Design and generation of recombinant rabies virus vectors</article-title><source>Nat. Protoc.</source><year>2013</year><volume>8</volume><fpage>1583</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.094</pub-id><?supplied-pmid 23887178?><pub-id pub-id-type="pmid">23887178</pub-id></element-citation></ref><ref id="B87-biomedicines-08-00060"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Measles McDonald</surname><given-names>C.J.</given-names></name><name><surname>Erlichman</surname><given-names>C.</given-names></name><name><surname>Ingle</surname><given-names>J.N.</given-names></name><name><surname>Rosales</surname><given-names>G.A.</given-names></name><name><surname>Allen</surname><given-names>C.</given-names></name><name><surname>Greiner</surname><given-names>S.M.</given-names></name><name><surname>Harvey</surname><given-names>M.E.</given-names></name><name><surname>Zollman</surname><given-names>P.J.</given-names></name><name><surname>Russell</surname><given-names>S.J.</given-names></name><name><surname>Galanis</surname><given-names>E.</given-names></name></person-group><article-title>A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer</article-title><source>Breast Cancer Res. Treat.</source><year>2006</year><volume>99</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/s10549-006-9200-5</pub-id><pub-id pub-id-type="pmid">16642271</pub-id></element-citation></ref><ref id="B88-biomedicines-08-00060"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lampe</surname><given-names>J.</given-names></name><name><surname>Bossow</surname><given-names>S.</given-names></name><name><surname>Weiland</surname><given-names>T.</given-names></name><name><surname>Smirnow</surname><given-names>I.</given-names></name><name><surname>Lehmann</surname><given-names>R.</given-names></name><name><surname>Neubert</surname><given-names>W.</given-names></name><name><surname>Bitzer</surname><given-names>M.</given-names></name><name><surname>Lauer</surname><given-names>U.M.</given-names></name></person-group><article-title>An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis</article-title><source>Gene Ther.</source><year>2013</year><volume>20</volume><fpage>1033</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1038/gt.2013.28</pub-id><pub-id pub-id-type="pmid">23719065</pub-id></element-citation></ref><ref id="B89-biomedicines-08-00060"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csatary</surname><given-names>L.K.</given-names></name><name><surname>Moss</surname><given-names>R.W.</given-names></name><name><surname>Beuth</surname><given-names>J.</given-names></name><name><surname>T&#x000f6;r&#x000f6;csik</surname><given-names>B.</given-names></name><name><surname>Szeberenyi</surname><given-names>J.</given-names></name><name><surname>Bakacs</surname><given-names>T.</given-names></name></person-group><article-title>Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H)</article-title><source>Anticancer Res.</source><year>1999</year><volume>19</volume><fpage>635</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">10216468</pub-id></element-citation></ref><ref id="B90-biomedicines-08-00060"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>New frontiers in oncolytic viruses: Optimizing and selecting for virus strains with improved efficacy</article-title><source>Biologics</source><year>2018</year><volume>12</volume><fpage>43</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.2147/BTT.S140114</pub-id><pub-id pub-id-type="pmid">29445265</pub-id></element-citation></ref><ref id="B91-biomedicines-08-00060"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>Z.</given-names></name><name><surname>Bai</surname><given-names>F.</given-names></name><name><surname>Sun</surname><given-names>T.</given-names></name><name><surname>Tian</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Cao</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Recombinant newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma model</article-title><source>Technol. Cancer Res. Treat.</source><year>2015</year><volume>14</volume><fpage>607</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.7785/tcrt.2012.500414</pub-id><pub-id pub-id-type="pmid">24645750</pub-id></element-citation></ref><ref id="B92-biomedicines-08-00060"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Fu</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer</article-title><source>Virol. J.</source><year>2014</year><volume>11</volume><fpage>84</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-11-84</pub-id><pub-id pub-id-type="pmid">24885546</pub-id></element-citation></ref><ref id="B93-biomedicines-08-00060"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>An</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy</article-title><source>J. Pharmacol. Sci.</source><year>2016</year><volume>132</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.jphs.2016.03.012</pub-id><pub-id pub-id-type="pmid">27174862</pub-id></element-citation></ref><ref id="B94-biomedicines-08-00060"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Geng</surname><given-names>J.</given-names></name><name><surname>An</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy</article-title><source>Eur. J. Pharmacol.</source><year>2017</year><volume>802</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2017.02.042</pub-id><pub-id pub-id-type="pmid">28246027</pub-id></element-citation></ref><ref id="B95-biomedicines-08-00060"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>S.</given-names></name><name><surname>Jakes</surname><given-names>A.D.</given-names></name><name><surname>Harrington</surname><given-names>K.</given-names></name><name><surname>Pandha</surname><given-names>H.</given-names></name><name><surname>Melcher</surname><given-names>A.</given-names></name><name><surname>Errington-Mais</surname><given-names>F.</given-names></name></person-group><article-title>Applications of coxsackievirus A21 in oncology</article-title><source>Oncolytic Virother.</source><year>2014</year><volume>3</volume><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.2147/OV.S56322</pub-id><pub-id pub-id-type="pmid">27512662</pub-id></element-citation></ref><ref id="B96-biomedicines-08-00060"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafren</surname><given-names>D.R.</given-names></name><name><surname>Au</surname><given-names>G.G.</given-names></name><name><surname>Nguyen</surname><given-names>T.</given-names></name><name><surname>Newcombe</surname><given-names>N.G.</given-names></name><name><surname>Haley</surname><given-names>E.S.</given-names></name><name><surname>Beagley</surname><given-names>L.</given-names></name><name><surname>Johansson</surname><given-names>E.S.</given-names></name><name><surname>Hersey</surname><given-names>P.</given-names></name><name><surname>Barry</surname><given-names>R.D.</given-names></name></person-group><article-title>Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21</article-title><source>Clin. Cancer Res.</source><year>2004</year><volume>10</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-0690-3</pub-id><pub-id pub-id-type="pmid">14734451</pub-id></element-citation></ref><ref id="B97-biomedicines-08-00060"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skelding</surname><given-names>K.A.</given-names></name><name><surname>Barry</surname><given-names>R.D.</given-names></name><name><surname>Shafren</surname><given-names>D.R.</given-names></name></person-group><article-title>Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21</article-title><source>Breast Cancer Res. Treat.</source><year>2009</year><volume>113</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s10549-008-9899-2</pub-id><pub-id pub-id-type="pmid">18256929</pub-id></element-citation></ref><ref id="B98-biomedicines-08-00060"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skelding</surname><given-names>K.A.</given-names></name><name><surname>Barry</surname><given-names>R.D.</given-names></name><name><surname>Shafren</surname><given-names>D.R.</given-names></name></person-group><article-title>Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride</article-title><source>Investig. New Drugs</source><year>2012</year><volume>30</volume><fpage>568</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1007/s10637-010-9614-0</pub-id><pub-id pub-id-type="pmid">21170760</pub-id></element-citation></ref><ref id="B99-biomedicines-08-00060"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>L.J.</given-names></name><name><surname>Au</surname><given-names>G.G.</given-names></name><name><surname>Barry</surname><given-names>R.D.</given-names></name><name><surname>Shafren</surname><given-names>D.R.</given-names></name></person-group><article-title>Potent oncolytic activity of human enteroviruses against human prostate cancer</article-title><source>Prostate</source><year>2008</year><volume>68</volume><fpage>577</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1002/pros.20741</pub-id><pub-id pub-id-type="pmid">18288643</pub-id></element-citation></ref><ref id="B100-biomedicines-08-00060"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>H.</given-names></name><name><surname>H&#x000f6;rig</surname><given-names>H.</given-names></name><name><surname>Kaufman</surname><given-names>H.L.</given-names></name></person-group><article-title>Poxviruses as vectors for cancer immunotherapy</article-title><source>Curr. Opin. Drug Discov. Devel.</source><year>2003</year><volume>6</volume><fpage>161</fpage><lpage>168</lpage></element-citation></ref><ref id="B101-biomedicines-08-00060"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeh</surname><given-names>H.J.</given-names></name><name><surname>Bartlett</surname><given-names>D.L.</given-names></name></person-group><article-title>Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers</article-title><source>Cancer Gene Ther.</source><year>2002</year><volume>9</volume><fpage>1001</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700549</pub-id><pub-id pub-id-type="pmid">12522439</pub-id></element-citation></ref><ref id="B102-biomedicines-08-00060"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastrangelo</surname><given-names>M.J.</given-names></name><name><surname>Lattime</surname><given-names>E.C.</given-names></name></person-group><article-title>Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors</article-title><source>Cancer Gene Ther.</source><year>2002</year><volume>9</volume><fpage>1013</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700538</pub-id><pub-id pub-id-type="pmid">12522440</pub-id></element-citation></ref><ref id="B103-biomedicines-08-00060"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madan</surname><given-names>R.A.</given-names></name><name><surname>Arlen</surname><given-names>P.M.</given-names></name><name><surname>Gulley</surname><given-names>J.L.</given-names></name></person-group><article-title>PANVAC-VF: Poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma</article-title><source>Expert Opin. Biol. Ther.</source><year>2007</year><volume>7</volume><fpage>543</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1517/14712598.7.4.543</pub-id><pub-id pub-id-type="pmid">17373905</pub-id></element-citation></ref><ref id="B104-biomedicines-08-00060"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansfield</surname><given-names>D.C.</given-names></name><name><surname>Kyula</surname><given-names>J.N.</given-names></name><name><surname>Rosenfelder</surname><given-names>N.</given-names></name><name><surname>Chao-Chu</surname><given-names>J.</given-names></name><name><surname>Kramer-Marek</surname><given-names>G.</given-names></name><name><surname>Khan</surname><given-names>A.A.</given-names></name><name><surname>Roulstone</surname><given-names>V.</given-names></name><name><surname>McLaughlin</surname><given-names>M.</given-names></name><name><surname>Melcher</surname><given-names>A.A.</given-names></name><name><surname>Vile</surname><given-names>R.G.</given-names></name><etal/></person-group><article-title>Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer</article-title><source>Gene Ther.</source><year>2016</year><volume>23</volume><fpage>357</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1038/gt.2016.5</pub-id><pub-id pub-id-type="pmid">26814609</pub-id></element-citation></ref><ref id="B105-biomedicines-08-00060"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricordel</surname><given-names>M.</given-names></name><name><surname>Foloppe</surname><given-names>J.</given-names></name><name><surname>Pichon</surname><given-names>C.</given-names></name><name><surname>Sfrontato</surname><given-names>N.</given-names></name><name><surname>Antoine</surname><given-names>D.</given-names></name><name><surname>Tosch</surname><given-names>C.</given-names></name><name><surname>Cochin</surname><given-names>S.</given-names></name><name><surname>Cordier</surname><given-names>P.</given-names></name><name><surname>Quemeneur</surname><given-names>E.</given-names></name><name><surname>Camus-Bouclainville</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Cowpox virus: A new and armed oncolytic poxvirus</article-title><source>Mol. Ther. Oncol.</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.omto.2017.08.003</pub-id></element-citation></ref><ref id="B106-biomedicines-08-00060"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duggal</surname><given-names>R.</given-names></name><name><surname>Geissinger</surname><given-names>U.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Aguilar</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>N.G.</given-names></name><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Vescovi</surname><given-names>A.L.</given-names></name><name><surname>Szalay</surname><given-names>A.A.</given-names></name></person-group><article-title>Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival</article-title><source>J. Transl. Med.</source><year>2013</year><volume>11</volume><fpage>155</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-11-155</pub-id><pub-id pub-id-type="pmid">23800258</pub-id></element-citation></ref><ref id="B107-biomedicines-08-00060"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>Self-replicating RNA viruses for RNA therapeutics</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>3310</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23123310</pub-id></element-citation></ref><ref id="B108-biomedicines-08-00060"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>M.S.</given-names></name><name><surname>Groene</surname><given-names>W.S.</given-names></name><name><surname>Lorence</surname><given-names>R.M.</given-names></name><name><surname>Bamat</surname><given-names>M.K.</given-names></name></person-group><article-title>Naturally occurring viruses for the treatment of cancer</article-title><source>Discov. Med.</source><year>2009</year><volume>6</volume><fpage>217</fpage><lpage>222</lpage></element-citation></ref><ref id="B109-biomedicines-08-00060"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prestwich</surname><given-names>R.J.</given-names></name><name><surname>Harrington</surname><given-names>K.J.</given-names></name><name><surname>Pandha</surname><given-names>H.S.</given-names></name><name><surname>Vile</surname><given-names>R.G.</given-names></name><name><surname>Melcher</surname><given-names>A.A.</given-names></name><name><surname>Errington</surname><given-names>F.</given-names></name></person-group><article-title>Oncolytic viruses: A novel form of immunotherapy</article-title><source>Expert Rev. Anticancer Ther.</source><year>2008</year><volume>8</volume><fpage>1581</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1586/14737140.8.10.1581</pub-id><pub-id pub-id-type="pmid">18925850</pub-id></element-citation></ref><ref id="B110-biomedicines-08-00060"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiocca</surname><given-names>E.</given-names></name><name><surname>Rabkin</surname><given-names>S.</given-names></name></person-group><article-title>Oncolytic viruses and their application to cancer immunotherapy</article-title><source>Cancer Immunol. Res.</source><year>2014</year><volume>2</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0015</pub-id><pub-id pub-id-type="pmid">24764576</pub-id></element-citation></ref><ref id="B111-biomedicines-08-00060"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurelian</surname><given-names>L.</given-names></name></person-group><article-title>Oncolytic viruses as immunotherapy: Progress and remaining challenges</article-title><source>Onco Targets Ther.</source><year>2016</year><volume>9</volume><fpage>2627</fpage><lpage>2637</lpage><pub-id pub-id-type="doi">10.2147/OTT.S63049</pub-id><pub-id pub-id-type="pmid">27226725</pub-id></element-citation></ref><ref id="B112-biomedicines-08-00060"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>E.</given-names></name><name><surname>Russell</surname><given-names>S.J.</given-names></name></person-group><article-title>History of oncolytic viruses: Genesis to genetic engineering</article-title><source>Mol. Ther.</source><year>2007</year><volume>15</volume><fpage>651</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/sj.mt.6300108</pub-id><pub-id pub-id-type="pmid">17299401</pub-id></element-citation></ref><ref id="B113-biomedicines-08-00060"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jhawar</surname><given-names>S.R.</given-names></name><name><surname>Thandoni</surname><given-names>A.</given-names></name><name><surname>Bommareddy</surname><given-names>P.K.</given-names></name><name><surname>Hassan</surname><given-names>S.</given-names></name><name><surname>Kohlhapp</surname><given-names>F.J.</given-names></name><name><surname>Goyal</surname><given-names>S.</given-names></name><name><surname>Schenkel</surname><given-names>J.M.</given-names></name><name><surname>Silk</surname><given-names>A.W.</given-names></name><name><surname>Zloza</surname><given-names>A.</given-names></name></person-group><article-title>Oncolytic viruses&#x02014;Natural and genetically engineered cancer immunotherapies</article-title><source>Front. Oncol.</source><year>2017</year><volume>7</volume><pub-id pub-id-type="doi">10.3389/fonc.2017.00202</pub-id></element-citation></ref><ref id="B114-biomedicines-08-00060"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bommareddy</surname><given-names>P.K.</given-names></name><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Hossain</surname><given-names>S.</given-names></name><name><surname>Kaufman</surname><given-names>H.L.</given-names></name></person-group><article-title>Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma</article-title><source>Am. J. Clin. Dermatol.</source><year>2017</year><volume>18</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s40257-016-0238-9</pub-id><pub-id pub-id-type="pmid">27988837</pub-id></element-citation></ref><ref id="B115-biomedicines-08-00060"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffin</surname><given-names>R.S.</given-names></name><name><surname>MacLean</surname><given-names>A.R.</given-names></name><name><surname>Latchman</surname><given-names>D.S.</given-names></name><name><surname>Brown</surname><given-names>S.M.</given-names></name></person-group><article-title>Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors</article-title><source>Gene Ther.</source><year>1996</year><volume>3</volume><fpage>886</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">8908502</pub-id></element-citation></ref><ref id="B116-biomedicines-08-00060"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andtbacka</surname><given-names>R.H.</given-names></name><name><surname>Curti</surname><given-names>B.D.</given-names></name><name><surname>Hallmeyer</surname><given-names>S.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Paustian</surname><given-names>C.</given-names></name><name><surname>Bifulco</surname><given-names>C.</given-names></name><name><surname>Fox</surname><given-names>B.</given-names></name><name><surname>Grose</surname><given-names>M.</given-names></name><name><surname>Shafren</surname><given-names>D.</given-names></name></person-group><article-title>Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment</article-title><source>J. Immunother. Cancer</source><year>2015</year><volume>3</volume><fpage>P343</fpage><pub-id pub-id-type="doi">10.1186/2051-1426-3-S2-P343</pub-id></element-citation></ref><ref id="B117-biomedicines-08-00060"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andtbacka</surname><given-names>R.H.I.</given-names></name><name><surname>Ross</surname><given-names>M.</given-names></name><name><surname>Puzanov</surname><given-names>I.</given-names></name><name><surname>Milhem</surname><given-names>M.</given-names></name><name><surname>Collichio</surname><given-names>F.</given-names></name><name><surname>Delman</surname><given-names>K.A.</given-names></name><name><surname>Amatruda</surname><given-names>T.</given-names></name><name><surname>Zager</surname><given-names>J.S.</given-names></name><name><surname>Cranmer</surname><given-names>L.</given-names></name><name><surname>Hsueh</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial</article-title><source>Ann. Surg Oncol.</source><year>2016</year><volume>23</volume><fpage>4169</fpage><lpage>4177</lpage><pub-id pub-id-type="doi">10.1245/s10434-016-5286-0</pub-id><pub-id pub-id-type="pmid">27342831</pub-id></element-citation></ref><ref id="B118-biomedicines-08-00060"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puzanov</surname><given-names>I.</given-names></name><name><surname>Milhem</surname><given-names>M.M.</given-names></name><name><surname>Minor</surname><given-names>D.</given-names></name><name><surname>Hamid</surname><given-names>O.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Chastain</surname><given-names>M.</given-names></name><name><surname>Gorski</surname><given-names>K.S.</given-names></name><name><surname>Anderson</surname><given-names>A.</given-names></name><name><surname>Chou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma</article-title><source>J. Clin. Oncol.</source><year>2016</year><pub-id pub-id-type="doi">10.1200/JCO.2016.67.1529</pub-id></element-citation></ref><ref id="B119-biomedicines-08-00060"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silk</surname><given-names>A.W.</given-names></name><name><surname>Kaufman</surname><given-names>H.</given-names></name><name><surname>Gabrail</surname><given-names>N.</given-names></name><name><surname>Mehnert</surname><given-names>J.</given-names></name><name><surname>Bryan</surname><given-names>J.</given-names></name><name><surname>Norrell</surname><given-names>J.</given-names></name><name><surname>Medina</surname><given-names>D.</given-names></name><name><surname>Bommareddy</surname><given-names>P.</given-names></name><name><surname>Shafren</surname><given-names>D.</given-names></name><name><surname>Grose</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial</article-title><source>Cancer Res.</source><year>2017</year><volume>77</volume><fpage>CT026</fpage></element-citation></ref><ref id="B120-biomedicines-08-00060"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>T.-M.</given-names></name><name><surname>Yao</surname><given-names>W.-Q.</given-names></name><name><surname>Chen</surname><given-names>L.-L.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.-L.</given-names></name><name><surname>Meng</surname><given-names>F.-J.</given-names></name></person-group><article-title>Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract</article-title><source>World J. Gastroenterol.</source><year>2003</year><volume>9</volume><fpage>495</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.3748/wjg.v9.i3.495</pub-id><pub-id pub-id-type="pmid">12632504</pub-id></element-citation></ref><ref id="B121-biomedicines-08-00060"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>Biology and application of alphaviruses in gene therapy</article-title><source>Gene Ther.</source><year>2005</year><volume>12</volume><fpage>S92</fpage><lpage>S97</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302620</pub-id><pub-id pub-id-type="pmid">16231060</pub-id></element-citation></ref><ref id="B122-biomedicines-08-00060"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>H.L.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name><name><surname>DeRaffele</surname><given-names>G.</given-names></name><name><surname>Mitcham</surname><given-names>J.</given-names></name><name><surname>Coffin</surname><given-names>R.S.</given-names></name><name><surname>Kim-Schulze</surname><given-names>S.</given-names></name></person-group><article-title>Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma</article-title><source>Ann. Surg Oncol.</source><year>2010</year><volume>17</volume><fpage>718</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1245/s10434-009-0809-6</pub-id><pub-id pub-id-type="pmid">19915919</pub-id></element-citation></ref><ref id="B123-biomedicines-08-00060"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.C.C.</given-names></name><name><surname>Coffin</surname><given-names>R.S.</given-names></name><name><surname>Davis</surname><given-names>C.J.</given-names></name><name><surname>Graham</surname><given-names>N.J.</given-names></name><name><surname>Groves</surname><given-names>N.</given-names></name><name><surname>Guest</surname><given-names>P.J.</given-names></name><name><surname>Harrington</surname><given-names>K.J.</given-names></name><name><surname>James</surname><given-names>N.D.</given-names></name><name><surname>Love</surname><given-names>C.A.</given-names></name><name><surname>McNeish</surname><given-names>I.</given-names></name><etal/></person-group><article-title>A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor</article-title><source>Clin. Cancer Res.</source><year>2006</year><volume>12</volume><fpage>6737</fpage><lpage>6747</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0759</pub-id><pub-id pub-id-type="pmid">17121894</pub-id></element-citation></ref><ref id="B124-biomedicines-08-00060"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senzer</surname><given-names>N.N.</given-names></name><name><surname>Kaufman</surname><given-names>H.L.</given-names></name><name><surname>Amatruda</surname><given-names>T.</given-names></name><name><surname>Nemunaitis</surname><given-names>M.</given-names></name><name><surname>Reid</surname><given-names>T.</given-names></name><name><surname>Daniels</surname><given-names>G.</given-names></name><name><surname>Gonzalez</surname><given-names>R.</given-names></name><name><surname>Glaspy</surname><given-names>J.</given-names></name><name><surname>Whitman</surname><given-names>E.</given-names></name><name><surname>Harrington</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor&#x02013;encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma</article-title><source>J. Clin. Oncol.</source><year>2009</year><volume>27</volume><fpage>5763</fpage><pub-id pub-id-type="doi">10.1200/JCO.2009.24.3675</pub-id><pub-id pub-id-type="pmid">19884534</pub-id></element-citation></ref><ref id="B125-biomedicines-08-00060"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherr</surname><given-names>M.</given-names></name><name><surname>Eder</surname><given-names>M.</given-names></name></person-group><article-title>Gene transfer into hematopoietic stem cells using lentiviral vectors</article-title><source>Curr. Gene Ther.</source><year>2002</year><volume>2</volume><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.2174/1566523023348237</pub-id><pub-id pub-id-type="pmid">12108973</pub-id></element-citation></ref><ref id="B126-biomedicines-08-00060"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavazzana-Calvo</surname><given-names>M.</given-names></name><name><surname>Hacein-Bey</surname><given-names>S.</given-names></name><name><surname>De Saint Basile</surname><given-names>G.</given-names></name><name><surname>Gross</surname><given-names>F.</given-names></name><name><surname>Yvon</surname><given-names>E.</given-names></name><name><surname>Nusbaum</surname><given-names>P.</given-names></name><name><surname>Selz</surname><given-names>F.</given-names></name><name><surname>Hue</surname><given-names>C.</given-names></name><name><surname>Certain</surname><given-names>S.</given-names></name><name><surname>Casanova</surname><given-names>J.-L.</given-names></name><etal/></person-group><article-title>Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease</article-title><source>Science</source><year>2000</year><volume>288</volume><fpage>669</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1126/science.288.5466.669</pub-id><pub-id pub-id-type="pmid">10784449</pub-id></element-citation></ref><ref id="B127-biomedicines-08-00060"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastide</surname><given-names>C.</given-names></name><name><surname>Maroc</surname><given-names>N.</given-names></name><name><surname>Bladou</surname><given-names>F.</given-names></name><name><surname>Hassoun</surname><given-names>J.</given-names></name><name><surname>Maitland</surname><given-names>N.</given-names></name><name><surname>Mannoni</surname><given-names>P.</given-names></name><name><surname>Bagnis</surname><given-names>C.</given-names></name></person-group><article-title>Expression of a model gene in prostate cancer cells lentivirally transduced in vitro and in vivo</article-title><source>Prostate Cancer Prostatic Dis.</source><year>2003</year><volume>6</volume><fpage>228</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1038/sj.pcan.4500668</pub-id><pub-id pub-id-type="pmid">12970726</pub-id></element-citation></ref><ref id="B128-biomedicines-08-00060"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name></person-group><article-title>Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model</article-title><source>Exp. Eye Res.</source><year>2018</year><volume>172</volume><fpage>144</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2018.04.009</pub-id><pub-id pub-id-type="pmid">29660328</pub-id></element-citation></ref><ref id="B129-biomedicines-08-00060"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name></person-group><article-title>Lentivirus-mediated downregulation of MAT2B inhibits cell proliferation and induces apoptosis in melanoma</article-title><source>Int. J. Oncol.</source><year>2016</year><volume>49</volume><fpage>981</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.3892/ijo.2016.3603</pub-id><pub-id pub-id-type="pmid">27573889</pub-id></element-citation></ref><ref id="B130-biomedicines-08-00060"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varas-Godoy</surname><given-names>M.</given-names></name><name><surname>Lladser</surname><given-names>A.</given-names></name><name><surname>Farfan</surname><given-names>N.</given-names></name><name><surname>Villota</surname><given-names>C.</given-names></name><name><surname>Villegas</surname><given-names>J.</given-names></name><name><surname>Tapia</surname><given-names>J.C.</given-names></name><name><surname>Burzio</surname><given-names>L.O.</given-names></name><name><surname>Burzio</surname><given-names>V.A.</given-names></name><name><surname>Valenzuela</surname><given-names>P.D.T.</given-names></name></person-group><article-title>In vivo knockdown of antisense non-coding mitochondrial RNAs by a lentiviral-encoded shRNA inhibits melanoma tumor growth and lung colonization</article-title><source>Pigment Cell Melanoma Res.</source><year>2018</year><volume>31</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12615</pub-id><pub-id pub-id-type="pmid">28707763</pub-id></element-citation></ref><ref id="B131-biomedicines-08-00060"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maude</surname><given-names>S.L.</given-names></name><name><surname>Frey</surname><given-names>N.</given-names></name><name><surname>Shaw</surname><given-names>P.A.</given-names></name><name><surname>Aplenc</surname><given-names>R.</given-names></name><name><surname>Barrett</surname><given-names>D.M.</given-names></name><name><surname>Bunin</surname><given-names>N.J.</given-names></name></person-group><article-title>Chimeric antigen receptor T cells for sustained remissions in leukemia</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>1507</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1407222</pub-id><pub-id pub-id-type="pmid">25317870</pub-id></element-citation></ref><ref id="B132-biomedicines-08-00060"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundarasetty</surname><given-names>B.S.</given-names></name><name><surname>Chan</surname><given-names>L.</given-names></name><name><surname>Darling</surname><given-names>D.</given-names></name><name><surname>Giunti</surname><given-names>G.</given-names></name><name><surname>Frazaneh</surname><given-names>F.</given-names></name><name><surname>Schemck</surname><given-names>F.</given-names></name><name><surname>Naundorf</surname><given-names>S.</given-names></name><name><surname>Kuehlcke</surname><given-names>K.</given-names></name><name><surname>Ruggiero</surname><given-names>E.</given-names></name><name><surname>Schmidt</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Lentivirus-induced &#x0201c;Smart&#x0201d;dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma</article-title><source>Gene Ther.</source><year>2015</year><volume>22</volume><fpage>707</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1038/gt.2015.43</pub-id><pub-id pub-id-type="pmid">25965393</pub-id></element-citation></ref><ref id="B133-biomedicines-08-00060"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>B.</given-names></name><name><surname>Harrer</surname><given-names>D.C.</given-names></name><name><surname>Thirion</surname><given-names>C.</given-names></name><name><surname>Schuler-Thurner</surname><given-names>B.</given-names></name><name><surname>Schuler</surname><given-names>G.</given-names></name><name><surname>Uslu</surname><given-names>U.</given-names></name></person-group><article-title>Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy</article-title><source>J. Immunol. Methods</source><year>2019</year><volume>472</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2019.06.015</pub-id><pub-id pub-id-type="pmid">31207210</pub-id></element-citation></ref><ref id="B134-biomedicines-08-00060"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milotou</surname><given-names>A.N.</given-names></name><name><surname>Papadopoulou</surname><given-names>L.C.</given-names></name></person-group><article-title>CAR T-cell therapy: A new era in cancer immunotherapy</article-title><source>Curr. Pharm. Biotechnol.</source><year>2018</year><volume>19</volume><fpage>5</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.2174/1389201019666180418095526</pub-id><?supplied-pmid 29667553?><pub-id pub-id-type="pmid">29667553</pub-id></element-citation></ref><ref id="B135-biomedicines-08-00060"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>B.</given-names></name><name><surname>Uslu</surname><given-names>U.</given-names></name></person-group><article-title>CAR-T cell therapy in melanoma: A future success story?</article-title><source>Exp. Dermatol.</source><year>2018</year><volume>27</volume><fpage>1315</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1111/exd.13792</pub-id><?supplied-pmid 30288790?><pub-id pub-id-type="pmid">30288790</pub-id></element-citation></ref><ref id="B136-biomedicines-08-00060"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodkin</surname><given-names>D.K.</given-names></name><name><surname>Nibert</surname><given-names>M.L.</given-names></name><name><surname>Fields</surname><given-names>B.N.</given-names></name></person-group><article-title>Proteolytic digestion of reovirus in the intestinal lumens of neonatal mice</article-title><source>J. Virol.</source><year>1989</year><volume>63</volume><fpage>4676</fpage><lpage>4681</lpage><pub-id pub-id-type="doi">10.1128/JVI.63.11.4676-4681.1989</pub-id><pub-id pub-id-type="pmid">2677401</pub-id></element-citation></ref><ref id="B137-biomedicines-08-00060"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strong</surname><given-names>J.E.</given-names></name><name><surname>Coffey</surname><given-names>M.C.</given-names></name><name><surname>Tang</surname><given-names>D.</given-names></name><name><surname>Sabinin</surname><given-names>P.</given-names></name><name><surname>Lee</surname><given-names>P.W.</given-names></name></person-group><article-title>The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus</article-title><source>EMBO J.</source><year>1998</year><volume>17</volume><fpage>3351</fpage><lpage>3362</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.12.3351</pub-id><pub-id pub-id-type="pmid">9628872</pub-id></element-citation></ref><ref id="B138-biomedicines-08-00060"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazarian</surname><given-names>R.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Kong</surname><given-names>X.</given-names></name><name><surname>Koya</surname><given-names>R.C.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Lee</surname><given-names>M.-K.</given-names></name><name><surname>Attar</surname><given-names>N.</given-names></name><name><surname>Sazegar</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</article-title><source>Nature</source><year>2010</year><volume>468</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09626</pub-id><pub-id pub-id-type="pmid">21107323</pub-id></element-citation></ref><ref id="B139-biomedicines-08-00060"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>F.</given-names></name><name><surname>White</surname><given-names>C.L.</given-names></name><name><surname>Twigger</surname><given-names>K.R.</given-names></name><name><surname>Rose</surname><given-names>A.</given-names></name><name><surname>Scott</surname><given-names>K.</given-names></name><name><surname>Steele</surname><given-names>L.</given-names></name><name><surname>Ilett</surname><given-names>L.J.</given-names></name><name><surname>Prestwich</surname><given-names>R.</given-names></name><name><surname>Pandha</surname><given-names>H.S.</given-names></name><name><surname>Coffey</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma</article-title><source>Gene Ther.</source><year>2008</year><volume>15</volume><fpage>1257</fpage><pub-id pub-id-type="doi">10.1038/gt.2008.58</pub-id><pub-id pub-id-type="pmid">18401435</pub-id></element-citation></ref><ref id="B140-biomedicines-08-00060"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashiro</surname><given-names>G.</given-names></name><name><surname>Loh</surname><given-names>P.C.</given-names></name><name><surname>Yau</surname><given-names>J.T.</given-names></name></person-group><article-title>The preferential cytotoxicity of reovirus for certain transformed cell lines</article-title><source>Arch. Virol.</source><year>1977</year><volume>54</volume><fpage>307</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1007/BF01314776</pub-id><pub-id pub-id-type="pmid">562142</pub-id></element-citation></ref><ref id="B141-biomedicines-08-00060"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffey</surname><given-names>M.C.</given-names></name><name><surname>Strong</surname><given-names>J.E.</given-names></name><name><surname>Forsyth</surname><given-names>P.A.</given-names></name><name><surname>Lee</surname><given-names>P.W.K.</given-names></name></person-group><article-title>Reovirus therapy of tumors with activated Ras pathway</article-title><source>Science</source><year>1998</year><volume>282</volume><fpage>1332</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1126/science.282.5392.1332</pub-id><pub-id pub-id-type="pmid">9812900</pub-id></element-citation></ref><ref id="B142-biomedicines-08-00060"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hata</surname><given-names>Y.</given-names></name><name><surname>Etoh</surname><given-names>T.</given-names></name><name><surname>Inomata</surname><given-names>M.</given-names></name><name><surname>Shiraishi</surname><given-names>N.</given-names></name><name><surname>Nishizono</surname><given-names>A.</given-names></name><name><surname>Kitano</surname><given-names>S.</given-names></name></person-group><article-title>Efficacy of oncolytic reovirus against human breast cancer cells</article-title><source>Oncol. Rep.</source><year>2008</year><volume>19</volume><fpage>1395</fpage><lpage>1398</lpage><pub-id pub-id-type="pmid">18497942</pub-id></element-citation></ref><ref id="B143-biomedicines-08-00060"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twigger</surname><given-names>K.</given-names></name><name><surname>Vidal</surname><given-names>L.</given-names></name><name><surname>White</surname><given-names>C.L.</given-names></name><name><surname>Bono</surname><given-names>J.S.D.</given-names></name><name><surname>Bhide</surname><given-names>S.</given-names></name><name><surname>Coffey</surname><given-names>M.</given-names></name><name><surname>Thompson</surname><given-names>B.</given-names></name><name><surname>Vile</surname><given-names>R.G.</given-names></name><name><surname>Heinemann</surname><given-names>L.</given-names></name><name><surname>Pandha</surname><given-names>H.S.</given-names></name><etal/></person-group><article-title>Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>912</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1400</pub-id><pub-id pub-id-type="pmid">18245555</pub-id></element-citation></ref><ref id="B144-biomedicines-08-00060"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>D.G.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>DiFrancesco</surname><given-names>L.M.</given-names></name><name><surname>Fonseca</surname><given-names>K.</given-names></name><name><surname>Forsyth</surname><given-names>P.A.</given-names></name><name><surname>Paterson</surname><given-names>A.H.</given-names></name><name><surname>Coffey</surname><given-names>M.C.</given-names></name><name><surname>Thompson</surname><given-names>B.</given-names></name></person-group><article-title>REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin<sup>&#x000ae;</sup>) in patients with advanced solid tumors</article-title><source>Investig. New Drugs</source><year>2013</year><volume>31</volume><fpage>696</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1007/s10637-012-9865-z</pub-id><pub-id pub-id-type="pmid">22886613</pub-id></element-citation></ref><ref id="B145-biomedicines-08-00060"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clements</surname><given-names>D.</given-names></name><name><surname>Helson</surname><given-names>E.</given-names></name><name><surname>Gujar</surname><given-names>S.A.</given-names></name><name><surname>Lee</surname><given-names>P.W.</given-names></name></person-group><article-title>Reovirus in cancer therapy: An evidence-based review</article-title><source>Oncolytic Virother.</source><year>2014</year><volume>3</volume><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">27512664</pub-id></element-citation></ref><ref id="B146-biomedicines-08-00060"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsyth</surname><given-names>P.</given-names></name><name><surname>Rold&#x000e1;n</surname><given-names>G.</given-names></name><name><surname>George</surname><given-names>D.</given-names></name><name><surname>Wallace</surname><given-names>C.</given-names></name><name><surname>Palmer</surname><given-names>C.A.</given-names></name><name><surname>Morris</surname><given-names>D.</given-names></name><name><surname>Cairncross</surname><given-names>G.</given-names></name><name><surname>Matthews</surname><given-names>M.V.</given-names></name><name><surname>Markert</surname><given-names>J.</given-names></name><name><surname>Gillespie</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas</article-title><source>Mol. Ther.</source><year>2008</year><volume>16</volume><fpage>627</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/sj.mt.6300403</pub-id><pub-id pub-id-type="pmid">18253152</pub-id></element-citation></ref><ref id="B147-biomedicines-08-00060"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kicielinski</surname><given-names>K.P.</given-names></name><name><surname>Chiocca</surname><given-names>E.A.</given-names></name><name><surname>Yu</surname><given-names>J.S.</given-names></name><name><surname>Gill</surname><given-names>G.M.</given-names></name><name><surname>Coffey</surname><given-names>M.</given-names></name><name><surname>Markert</surname><given-names>J.M.</given-names></name></person-group><article-title>Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults</article-title><source>Mol. Ther.</source><year>2014</year><volume>22</volume><fpage>1056</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1038/mt.2014.21</pub-id><pub-id pub-id-type="pmid">24553100</pub-id></element-citation></ref><ref id="B148-biomedicines-08-00060"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gollamudi</surname><given-names>R.</given-names></name><name><surname>Ghalib</surname><given-names>M.H.</given-names></name><name><surname>Desai</surname><given-names>K.K.</given-names></name><name><surname>Chaudhary</surname><given-names>I.</given-names></name><name><surname>Wong</surname><given-names>B.</given-names></name><name><surname>Einstein</surname><given-names>M.</given-names></name><name><surname>Coffey</surname><given-names>M.</given-names></name><name><surname>Gill</surname><given-names>G.M.</given-names></name><name><surname>Mettinger</surname><given-names>K.</given-names></name><name><surname>Mariadason</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Intravenous administration of Reolysin<sup>&#x000ae;</sup>, a live replication competent RNA virus is safe in patients with advanced solid tumors</article-title><source>Investig. New Drugs</source><year>2010</year><volume>28</volume><fpage>641</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1007/s10637-009-9279-8</pub-id><pub-id pub-id-type="pmid">19572105</pub-id></element-citation></ref><ref id="B149-biomedicines-08-00060"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidal</surname><given-names>L.</given-names></name><name><surname>Pandha</surname><given-names>H.S.</given-names></name><name><surname>Yap</surname><given-names>T.A.</given-names></name><name><surname>White</surname><given-names>C.L.</given-names></name><name><surname>Twigger</surname><given-names>K.</given-names></name><name><surname>Vile</surname><given-names>R.G.</given-names></name><name><surname>Melcher</surname><given-names>A.</given-names></name><name><surname>Coffey</surname><given-names>M.</given-names></name><name><surname>Harrington</surname><given-names>K.J.</given-names></name><name><surname>DeBono</surname><given-names>J.S.</given-names></name></person-group><article-title>A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>7127</fpage><lpage>7137</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0524</pub-id><pub-id pub-id-type="pmid">18981012</pub-id></element-citation></ref><ref id="B150-biomedicines-08-00060"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>S.</given-names></name><name><surname>Kaur</surname><given-names>J.</given-names></name><name><surname>Patel</surname><given-names>K.D.</given-names></name></person-group><article-title>Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation</article-title><source>Am. J. Pathol.</source><year>2000</year><volume>157</volume><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64542-7</pub-id><pub-id pub-id-type="pmid">10880401</pub-id></element-citation></ref><ref id="B151-biomedicines-08-00060"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname><given-names>G.G.</given-names></name><name><surname>Beagley</surname><given-names>L.G.</given-names></name><name><surname>Haley</surname><given-names>E.S.</given-names></name><name><surname>Barry</surname><given-names>R.D.</given-names></name><name><surname>Shafren</surname><given-names>D.R.</given-names></name></person-group><article-title>Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18</article-title><source>Virol. J.</source><year>2011</year><volume>8</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-22</pub-id><pub-id pub-id-type="pmid">21241513</pub-id></element-citation></ref><ref id="B152-biomedicines-08-00060"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newcombe</surname><given-names>N.G.</given-names></name><name><surname>Beagley</surname><given-names>L.G.</given-names></name><name><surname>Christiansen</surname><given-names>D.</given-names></name><name><surname>Loveland</surname><given-names>B.E.</given-names></name><name><surname>Johansson</surname><given-names>E.S.</given-names></name><name><surname>Beagley</surname><given-names>K.W.</given-names></name><name><surname>Barry</surname><given-names>R.D.</given-names></name><name><surname>Shafren</surname><given-names>D.R.</given-names></name></person-group><article-title>Novel role for decay-accelerating factor in Coxsackievirus A21-mediated cell infectivity</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>12677</fpage><lpage>12682</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.22.12677-12682.2004</pub-id><pub-id pub-id-type="pmid">15507656</pub-id></element-citation></ref><ref id="B153-biomedicines-08-00060"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annels</surname><given-names>N.E.</given-names></name><name><surname>Mansfield</surname><given-names>D.</given-names></name><name><surname>Arif</surname><given-names>M.</given-names></name><name><surname>Ballesteros-Merino</surname><given-names>C.</given-names></name><name><surname>Simpson</surname><given-names>G.R.</given-names></name><name><surname>Denyer</surname><given-names>M.</given-names></name><name><surname>Sandhu</surname><given-names>S.S.</given-names></name><name><surname>Melcher</surname><given-names>A.A.</given-names></name><name><surname>Harrington</surname><given-names>K.J.</given-names></name><name><surname>Davies</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Phase I trial of an ICAM-1-targeted immunotherapeutic-Coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer</article-title><source>Clin. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>5818</fpage><lpage>5831</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-4022</pub-id><pub-id pub-id-type="pmid">31273010</pub-id></element-citation></ref><ref id="B154-biomedicines-08-00060"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafren</surname><given-names>D.R.</given-names></name><name><surname>Dorahy</surname><given-names>D.J.</given-names></name><name><surname>Ingham</surname><given-names>R.A.</given-names></name><name><surname>Burns</surname><given-names>G.F.</given-names></name><name><surname>Barry</surname><given-names>R.D.</given-names></name></person-group><article-title>Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry</article-title><source>J. Virol.</source><year>1997</year><volume>71</volume><fpage>4736</fpage><lpage>4743</lpage><pub-id pub-id-type="doi">10.1128/JVI.71.6.4736-4743.1997</pub-id><pub-id pub-id-type="pmid">9151867</pub-id></element-citation></ref><ref id="B155-biomedicines-08-00060"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>E.S.</given-names></name><name><surname>Xing</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>R.H.</given-names></name><name><surname>Shafren</surname><given-names>D.R.</given-names></name></person-group><article-title>Enhanced cellular receptor usage by a bioselected variant of Coxsackievirus A21</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>12603</fpage><lpage>12612</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.22.12603-12612.2004</pub-id><pub-id pub-id-type="pmid">15507647</pub-id></element-citation></ref><ref id="B156-biomedicines-08-00060"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kageshita</surname><given-names>T.</given-names></name><name><surname>Ono</surname><given-names>T.</given-names></name></person-group><article-title>Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma</article-title><source>J. Dermatol. Sci.</source><year>1993</year><volume>6</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1016/0923-1811(93)90825-A</pub-id></element-citation></ref><ref id="B157-biomedicines-08-00060"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komi</surname><given-names>J.</given-names></name><name><surname>Lassila</surname><given-names>O.</given-names></name></person-group><article-title>Toremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and jurkat cells</article-title><source>Scand. J. Immunol.</source><year>2000</year><volume>51</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3083.2000.00653.x</pub-id><pub-id pub-id-type="pmid">10632979</pub-id></element-citation></ref><ref id="B158-biomedicines-08-00060"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname><given-names>G.G.</given-names></name><name><surname>Lincz</surname><given-names>L.F.</given-names></name><name><surname>Enno</surname><given-names>A.</given-names></name><name><surname>Shafren</surname><given-names>D.R.</given-names></name></person-group><article-title>Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma</article-title><source>Br. J. Haematol.</source><year>2007</year><volume>137</volume><fpage>133</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2007.06550.x</pub-id><pub-id pub-id-type="pmid">17391493</pub-id></element-citation></ref><ref id="B159-biomedicines-08-00060"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miele</surname><given-names>M.E.</given-names></name><name><surname>Bennett</surname><given-names>C.F.</given-names></name><name><surname>Miller</surname><given-names>B.E.</given-names></name><name><surname>Welch</surname><given-names>D.R.</given-names></name></person-group><article-title>Enhanced metastatic ability of TNF-&#x003b1;-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides</article-title><source>Exp. Cell Res.</source><year>1994</year><volume>214</volume><fpage>231</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1006/excr.1994.1253</pub-id><pub-id pub-id-type="pmid">7915992</pub-id></element-citation></ref><ref id="B160-biomedicines-08-00060"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname><given-names>G.G.</given-names></name><name><surname>Lindberg</surname><given-names>A.M.</given-names></name><name><surname>Barry</surname><given-names>R.D.</given-names></name><name><surname>Shafren</surname><given-names>D.R.</given-names></name></person-group><article-title>Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21</article-title><source>Int. J. Oncol.</source><year>2005</year><volume>26</volume><fpage>1471</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.3892/ijo.26.6.1471</pub-id><pub-id pub-id-type="pmid">15870858</pub-id></element-citation></ref><ref id="B161-biomedicines-08-00060"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dharmadhikari</surname><given-names>N.</given-names></name><name><surname>Mehnert</surname><given-names>J.M.</given-names></name><name><surname>Kaufman</surname><given-names>H.L.</given-names></name></person-group><article-title>Oncolytic virus immunotherapy for melanoma</article-title><source>Curr. Treat. Options Oncol.</source><year>2015</year><volume>16</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1007/s11864-014-0326-0</pub-id></element-citation></ref><ref id="B162-biomedicines-08-00060"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eissa</surname><given-names>I.R.</given-names></name><name><surname>Bustos-Villalobos</surname><given-names>I.</given-names></name><name><surname>Ichinose</surname><given-names>T.</given-names></name><name><surname>Matsumura</surname><given-names>S.</given-names></name><name><surname>Naoe</surname><given-names>Y.</given-names></name><name><surname>Miyajima</surname><given-names>N.</given-names></name><name><surname>Morimoto</surname><given-names>D.</given-names></name><name><surname>Mukoyama</surname><given-names>N.</given-names></name><name><surname>Zhiwen</surname><given-names>W.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers</article-title><source>Cancers (Basel)</source><year>2018</year><volume>10</volume><elocation-id>356</elocation-id><pub-id pub-id-type="doi">10.3390/cancers10100356</pub-id></element-citation></ref><ref id="B163-biomedicines-08-00060"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curti</surname><given-names>B.D.</given-names></name><name><surname>Richards</surname><given-names>J.M.</given-names></name><name><surname>Hallmeyer</surname><given-names>S.</given-names></name><name><surname>Faries</surname><given-names>M.B.</given-names></name><name><surname>Andtbacka</surname><given-names>R.H.I.</given-names></name><name><surname>Daniels</surname><given-names>G.A.</given-names></name><name><surname>Grose</surname><given-names>M.</given-names></name><name><surname>Shafren</surname><given-names>D.</given-names></name></person-group><article-title>Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy</article-title><source>J. Clin. Oncol.</source><year>2017</year><volume>35</volume><fpage>3014</fpage><pub-id pub-id-type="doi">10.1200/JCO.2017.35.15_suppl.3014</pub-id></element-citation></ref><ref id="B164-biomedicines-08-00060"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.-H.</given-names></name><name><surname>Samal</surname><given-names>S.K.</given-names></name></person-group><article-title>Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines</article-title><source>Viruses</source><year>2016</year><volume>8</volume><elocation-id>183</elocation-id><pub-id pub-id-type="doi">10.3390/v8070183</pub-id><?supplied-pmid 27384578?><pub-id pub-id-type="pmid">27384578</pub-id></element-citation></ref><ref id="B165-biomedicines-08-00060"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>RNA viruses as tools in gene therapy and vaccine development</article-title><source>Genes</source><year>2019</year><volume>10</volume><elocation-id>189</elocation-id><pub-id pub-id-type="doi">10.3390/genes10030189</pub-id><?supplied-pmid 30832256?><pub-id pub-id-type="pmid">30832256</pub-id></element-citation></ref><ref id="B166-biomedicines-08-00060"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zsak</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name></person-group><article-title>Development of a Newcastle disease virus vector expressing a foreign gene through an internal ribosomal entry site provides direct proof for a sequential transcription mechanism</article-title><source>J. Gen. Virol.</source><year>2015</year><volume>96</volume><fpage>2028</fpage><lpage>2035</lpage><pub-id pub-id-type="doi">10.1099/vir.0.000142</pub-id><pub-id pub-id-type="pmid">25872740</pub-id></element-citation></ref><ref id="B167-biomedicines-08-00060"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>Shao</surname><given-names>H.</given-names></name><name><surname>Luo</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Development of a novel thermostable Newcastle disease virus vaccine vector for expression of a heterologous gene</article-title><source>J. Gen. Virol.</source><year>2015</year><volume>96</volume><fpage>1219</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1099/vir.0.000067</pub-id><?supplied-pmid 25626679?><pub-id pub-id-type="pmid">25626679</pub-id></element-citation></ref><ref id="B168-biomedicines-08-00060"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phuangsab</surname><given-names>A.</given-names></name><name><surname>Lorence</surname><given-names>R.M.</given-names></name><name><surname>Reichard</surname><given-names>K.W.</given-names></name><name><surname>Peeples</surname><given-names>M.E.</given-names></name><name><surname>Walter</surname><given-names>R.J.</given-names></name></person-group><article-title>Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration</article-title><source>Cancer Lett.</source><year>2001</year><volume>172</volume><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(01)00617-6</pub-id><pub-id pub-id-type="pmid">11595126</pub-id></element-citation></ref><ref id="B169-biomedicines-08-00060"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdullahi</surname><given-names>S.</given-names></name><name><surname>J&#x000e4;kel</surname><given-names>M.</given-names></name><name><surname>Behrend</surname><given-names>S.J.</given-names></name><name><surname>Steiger</surname><given-names>K.</given-names></name><name><surname>Topping</surname><given-names>G.</given-names></name><name><surname>Krabbe</surname><given-names>T.</given-names></name><name><surname>Colombo</surname><given-names>A.</given-names></name><name><surname>Sandig</surname><given-names>V.</given-names></name><name><surname>Schiergens</surname><given-names>T.S.</given-names></name><name><surname>Thasler</surname><given-names>W.E.</given-names></name><etal/></person-group><article-title>A novel chimeric oncolytic virus vector for improved safety and efficacy as a platform for the treatment of hepatocellular carcinoma</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><pub-id pub-id-type="doi">10.1128/JVI.01386-18</pub-id><?supplied-pmid 30232179?><pub-id pub-id-type="pmid">30232179</pub-id></element-citation></ref><ref id="B170-biomedicines-08-00060"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirrmacher</surname><given-names>V.</given-names></name></person-group><article-title>Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory</article-title><source>Cancer Immunol. Immunother.</source><year>2005</year><volume>54</volume><fpage>587</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1007/s00262-004-0602-0</pub-id><pub-id pub-id-type="pmid">15838708</pub-id></element-citation></ref><ref id="B171-biomedicines-08-00060"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voit</surname><given-names>C.</given-names></name><name><surname>Kron</surname><given-names>M.</given-names></name><name><surname>Schw&#x000fc;rzer-Voit</surname><given-names>M.</given-names></name><name><surname>Sterry</surname><given-names>W.</given-names></name></person-group><article-title>Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease</article-title><source>J. Dtsch. Dermatol. Ges.</source><year>2003</year><volume>1</volume><fpage>120</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1046/j.1610-0387.2003.02014.x</pub-id><pub-id pub-id-type="pmid">16285179</pub-id></element-citation></ref><ref id="B172-biomedicines-08-00060"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulze</surname><given-names>T.</given-names></name><name><surname>Kemmer</surname><given-names>W.</given-names></name><name><surname>Weitz</surname><given-names>J.</given-names></name><name><surname>Wernecke</surname><given-names>K.D.</given-names></name><name><surname>Schirrmacher</surname><given-names>V.</given-names></name><name><surname>Schlag</surname><given-names>P.M.</given-names></name></person-group><article-title>Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastasis: Results of a prospective randomized trial</article-title><source>Cancer Immunol. Immunother.</source><year>2009</year><volume>58</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s00262-008-0526-1</pub-id><pub-id pub-id-type="pmid">18488223</pub-id></element-citation></ref><ref id="B173-biomedicines-08-00060"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liljestr&#x000f6;m</surname><given-names>P.</given-names></name><name><surname>Garoff</surname><given-names>H.</given-names></name></person-group><article-title>A new generation of animal cell expression vectors based on the Semliki Forest virus replicon</article-title><source>Nat. Biotechnol.</source><year>1991</year><volume>9</volume><fpage>1356</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1038/nbt1291-1356</pub-id></element-citation></ref><ref id="B174-biomedicines-08-00060"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>C.</given-names></name><name><surname>Levis</surname><given-names>R.</given-names></name><name><surname>Shen</surname><given-names>P.</given-names></name><name><surname>Schlesinger</surname><given-names>S.</given-names></name><name><surname>Rice</surname><given-names>C.M.</given-names></name><name><surname>Huang</surname><given-names>H.V.</given-names></name></person-group><article-title>Sindbis virus: An efficient, broad host range vector for gene expression in animal cells</article-title><source>Science</source><year>1989</year><volume>243</volume><fpage>1188</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1126/science.2922607</pub-id><?supplied-pmid 2922607?><pub-id pub-id-type="pmid">2922607</pub-id></element-citation></ref><ref id="B175-biomedicines-08-00060"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>N.L.</given-names></name><name><surname>Willis</surname><given-names>L.V.</given-names></name><name><surname>Smith</surname><given-names>J.F.</given-names></name><name><surname>Johnston</surname><given-names>R.E.</given-names></name></person-group><article-title>In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant</article-title><source>Virology</source><year>1989</year><volume>171</volume><fpage>189</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(89)90526-6</pub-id><pub-id pub-id-type="pmid">2525837</pub-id></element-citation></ref><ref id="B176-biomedicines-08-00060"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>J.-C.</given-names></name><name><surname>Levin</surname><given-names>B.</given-names></name><name><surname>Hurtado</surname><given-names>A.</given-names></name><name><surname>Yee</surname><given-names>H.</given-names></name><name><surname>De Castro</surname><given-names>I.P.</given-names></name><name><surname>Jimenez</surname><given-names>M.</given-names></name><name><surname>Shamamian</surname><given-names>P.</given-names></name><name><surname>Jin</surname><given-names>R.</given-names></name><name><surname>Novick</surname><given-names>R.P.</given-names></name><name><surname>Pellicer</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Systemic tumor targeting and killing by Sindbis viral vectors</article-title><source>Nat. Biotechnol.</source><year>2004</year><volume>22</volume><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/nbt917</pub-id><pub-id pub-id-type="pmid">14647305</pub-id></element-citation></ref><ref id="B177-biomedicines-08-00060"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Madoz</surname><given-names>J.R.</given-names></name><name><surname>Prieto</surname><given-names>J.</given-names></name><name><surname>Smerdou</surname><given-names>C.</given-names></name></person-group><article-title>Biodistribution and tumor infectivity of semliki forest virus vectors in mice: Effects of re-administration</article-title><source>Mol. Ther.</source><year>2007</year><volume>15</volume><fpage>2164</fpage><lpage>2171</lpage><pub-id pub-id-type="doi">10.1038/sj.mt.6300274</pub-id><?supplied-pmid 17667947?><pub-id pub-id-type="pmid">17667947</pub-id></element-citation></ref><ref id="B178-biomedicines-08-00060"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>Plasmid DNA-based alphavirus vaccines</article-title><source>Vaccines (Basel)</source><year>2019</year><volume>7</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines7010029</pub-id><?supplied-pmid 30857255?><pub-id pub-id-type="pmid">30857255</pub-id></element-citation></ref><ref id="B179-biomedicines-08-00060"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riezebos-Brilman</surname><given-names>A.</given-names></name><name><surname>Walczak</surname><given-names>M.</given-names></name><name><surname>Regts</surname><given-names>J.</given-names></name><name><surname>Rots</surname><given-names>M.G.</given-names></name><name><surname>Kamps</surname><given-names>G.</given-names></name><name><surname>Dontje</surname><given-names>B.</given-names></name><name><surname>Haisma</surname><given-names>H.Y.</given-names></name><name><surname>Wilschut</surname><given-names>J.</given-names></name><name><surname>Daemen</surname><given-names>T.</given-names></name></person-group><article-title>A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer</article-title><source>Gene Ther.</source><year>2007</year><volume>14</volume><fpage>1695</fpage><lpage>1704</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3303036</pub-id><?supplied-pmid 17928874?><pub-id pub-id-type="pmid">17928874</pub-id></element-citation></ref><ref id="B180-biomedicines-08-00060"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hariharan</surname><given-names>M.J.</given-names></name><name><surname>Driver</surname><given-names>D.A.</given-names></name><name><surname>Townsend</surname><given-names>K.</given-names></name><name><surname>Brumm</surname><given-names>D.</given-names></name><name><surname>Polo</surname><given-names>J.M.</given-names></name><name><surname>Belli</surname><given-names>B.A.</given-names></name><name><surname>Catton</surname><given-names>D.J.</given-names></name><name><surname>Hsu</surname><given-names>D.</given-names></name><name><surname>Mittelstaedt</surname><given-names>D.</given-names></name><name><surname>McCormack</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>DNA immunization against herpes simplex virus: Enhanced efficacy using a sindbis virus-based vector</article-title><source>J. Virol.</source><year>1998</year><volume>72</volume><fpage>950</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1128/JVI.72.2.950-958.1998</pub-id><pub-id pub-id-type="pmid">9444987</pub-id></element-citation></ref><ref id="B181-biomedicines-08-00060"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>J.R.</given-names></name><name><surname>Kwang</surname><given-names>J.</given-names></name><name><surname>Varthakavi</surname><given-names>V.</given-names></name><name><surname>Lechtenberg</surname><given-names>K.F.</given-names></name><name><surname>Minocha</surname><given-names>H.C.</given-names></name></person-group><article-title>Semliki forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells</article-title><source>Comp. Immunol. Microbiol. Infect. Dis.</source><year>1999</year><volume>22</volume><fpage>231</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/S0147-9571(99)00014-4</pub-id><pub-id pub-id-type="pmid">10465327</pub-id></element-citation></ref><ref id="B182-biomedicines-08-00060"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>M.L.</given-names></name><name><surname>Ljungberg</surname><given-names>K.</given-names></name><name><surname>Tatoud</surname><given-names>R.</given-names></name><name><surname>Weber</surname><given-names>J.</given-names></name><name><surname>Esteban</surname><given-names>M.</given-names></name><name><surname>Liljestr&#x000f6;m</surname><given-names>P.</given-names></name></person-group><article-title>Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia ankara (MVA) or with HIV gp140 protein antigen</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0117042</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0117042</pub-id><pub-id pub-id-type="pmid">25643354</pub-id></element-citation></ref><ref id="B183-biomedicines-08-00060"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>S.</given-names></name><name><surname>Sonwane</surname><given-names>A.A.</given-names></name><name><surname>Dahiya</surname><given-names>S.S.</given-names></name><name><surname>Patel</surname><given-names>C.L.</given-names></name><name><surname>Saini</surname><given-names>M.</given-names></name><name><surname>Rai</surname><given-names>A.</given-names></name><name><surname>Gupta</surname><given-names>P.K.</given-names></name></person-group><article-title>Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein</article-title><source>Vet. Microbiol.</source><year>2009</year><volume>136</volume><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2008.10.030</pub-id><pub-id pub-id-type="pmid">19081687</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="biomedicines-08-00060-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">biomedicines-08-00060-t001_Table 1</object-id><label>Table 1</label><caption><p>Viruses and their vectors applied in overall gene therapy [<xref rid="B36-biomedicines-08-00060" ref-type="bibr">36</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genome</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Types</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenovirus<break/>Ad5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dsDNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong immunogenicity Broad host range<break/>[<xref rid="B37-biomedicines-08-00060" ref-type="bibr">37</xref>,<xref rid="B38-biomedicines-08-00060" ref-type="bibr">38</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain [<xref rid="B39-biomedicines-08-00060" ref-type="bibr">39</xref>]<break/>Colon [<xref rid="B40-biomedicines-08-00060" ref-type="bibr">40</xref>,<xref rid="B41-biomedicines-08-00060" ref-type="bibr">41</xref>]<break/> Esophaegal [<xref rid="B42-biomedicines-08-00060" ref-type="bibr">42</xref>]<break/>Gastric [<xref rid="B43-biomedicines-08-00060" ref-type="bibr">43</xref>]<break/>Liver [<xref rid="B44-biomedicines-08-00060" ref-type="bibr">44</xref>]<break/>Lung [<xref rid="B45-biomedicines-08-00060" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adeno associated viruses<break/>AAV (2, 3, 5, 6, 8, 9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ssDNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Slow expression onset<break/>Chromosomal integration<break/>[<xref rid="B46-biomedicines-08-00060" ref-type="bibr">46</xref>,<xref rid="B47-biomedicines-08-00060" ref-type="bibr">47</xref>,<xref rid="B48-biomedicines-08-00060" ref-type="bibr">48</xref>,<xref rid="B49-biomedicines-08-00060" ref-type="bibr">49</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain [<xref rid="B50-biomedicines-08-00060" ref-type="bibr">50</xref>]<break/>Breast [<xref rid="B51-biomedicines-08-00060" ref-type="bibr">51</xref>]<break/>Liver [<xref rid="B52-biomedicines-08-00060" ref-type="bibr">52</xref>,<xref rid="B53-biomedicines-08-00060" ref-type="bibr">53</xref>]<break/>Lung [<xref rid="B54-biomedicines-08-00060" ref-type="bibr">54</xref>]<break/>Prostate [<xref rid="B55-biomedicines-08-00060" ref-type="bibr">55</xref>]<break/>Retinoblastoma [<xref rid="B56-biomedicines-08-00060" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alphaviruses<break/>SFV, SIN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ssRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad host range<break/>low immunogenicity<break/>[<xref rid="B32-biomedicines-08-00060" ref-type="bibr">32</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain [<xref rid="B57-biomedicines-08-00060" ref-type="bibr">57</xref>]<break/>Colon [<xref rid="B58-biomedicines-08-00060" ref-type="bibr">58</xref>]<break/>Lung [<xref rid="B59-biomedicines-08-00060" ref-type="bibr">59</xref>]<break/>Melanoma [<xref rid="B60-biomedicines-08-00060" ref-type="bibr">60</xref>,<xref rid="B61-biomedicines-08-00060" ref-type="bibr">61</xref>]<break/>Osteosarcoma [<xref rid="B62-biomedicines-08-00060" ref-type="bibr">62</xref>]<break/>Pancreas [<xref rid="B63-biomedicines-08-00060" ref-type="bibr">63</xref>]<break/>Prostate [<xref rid="B64-biomedicines-08-00060" ref-type="bibr">64</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Herpes simplex virus HSV1, HSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dsDNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad host range<break/>Latent infection<break/>[<xref rid="B65-biomedicines-08-00060" ref-type="bibr">65</xref>,<xref rid="B66-biomedicines-08-00060" ref-type="bibr">66</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain [<xref rid="B67-biomedicines-08-00060" ref-type="bibr">67</xref>,<xref rid="B68-biomedicines-08-00060" ref-type="bibr">68</xref>]<break/>Colon [<xref rid="B69-biomedicines-08-00060" ref-type="bibr">69</xref>]<break/>Prostate [<xref rid="B70-biomedicines-08-00060" ref-type="bibr">70</xref>]<break/>Sarcoma [<xref rid="B71-biomedicines-08-00060" ref-type="bibr">71</xref>]<break/>Skin [<xref rid="B72-biomedicines-08-00060" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reoviruses<break/>Reolysin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dsDNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specific replication in transformed host cells Non-pathogenic in human Anti-cancer activity</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma [<xref rid="B73-biomedicines-08-00060" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retroviruses<break/>MMSV MSCV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ssRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Random integration Long-term expression<break/>[<xref rid="B74-biomedicines-08-00060" ref-type="bibr">74</xref>,<xref rid="B75-biomedicines-08-00060" ref-type="bibr">75</xref>,<xref rid="B76-biomedicines-08-00060" ref-type="bibr">76</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Glioma [<xref rid="B77-biomedicines-08-00060" ref-type="bibr">77</xref>,<xref rid="B78-biomedicines-08-00060" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lentiviruses<break/>HIV-1, HIV-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ssRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad host range<break/>Low cytotoxicity<break/>[<xref rid="B76-biomedicines-08-00060" ref-type="bibr">76</xref>,<xref rid="B79-biomedicines-08-00060" ref-type="bibr">79</xref>,<xref rid="B80-biomedicines-08-00060" ref-type="bibr">80</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast [<xref rid="B81-biomedicines-08-00060" ref-type="bibr">81</xref>]<break/>Gastric [<xref rid="B82-biomedicines-08-00060" ref-type="bibr">82</xref>]<break/>Liver [<xref rid="B83-biomedicines-08-00060" ref-type="bibr">83</xref>]<break/>Pancreas [<xref rid="B84-biomedicines-08-00060" ref-type="bibr">84</xref>]<break/>Leukemia [<xref rid="B85-biomedicines-08-00060" ref-type="bibr">85</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rhabdoviruses Rabies, VSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ssRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low immunogenicity<break/>High transient expression [<xref rid="B86-biomedicines-08-00060" ref-type="bibr">86</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarcoma [<xref rid="B86-biomedicines-08-00060" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measels virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ssRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncolytic strains<break/>[<xref rid="B87-biomedicines-08-00060" ref-type="bibr">87</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast [<xref rid="B87-biomedicines-08-00060" ref-type="bibr">87</xref>]<break/>Liver [<xref rid="B88-biomedicines-08-00060" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Newcastle disease virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ssRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved oncolytic virus<break/>[<xref rid="B89-biomedicines-08-00060" ref-type="bibr">89</xref>,<xref rid="B90-biomedicines-08-00060" ref-type="bibr">90</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma [<xref rid="B91-biomedicines-08-00060" ref-type="bibr">91</xref>]<break/>Lung [<xref rid="B92-biomedicines-08-00060" ref-type="bibr">92</xref>]<break/>Liver [<xref rid="B93-biomedicines-08-00060" ref-type="bibr">93</xref>,<xref rid="B94-biomedicines-08-00060" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Picornaviruses</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ssRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncolytic strains<break/>[<xref rid="B95-biomedicines-08-00060" ref-type="bibr">95</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma [<xref rid="B96-biomedicines-08-00060" ref-type="bibr">96</xref>]<break/>Breast [<xref rid="B97-biomedicines-08-00060" ref-type="bibr">97</xref>,<xref rid="B98-biomedicines-08-00060" ref-type="bibr">98</xref>]<break/>Prostate [<xref rid="B99-biomedicines-08-00060" ref-type="bibr">99</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poxviruses</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dsDNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved oncolytic virus<break/>[<xref rid="B100-biomedicines-08-00060" ref-type="bibr">100</xref>,<xref rid="B101-biomedicines-08-00060" ref-type="bibr">101</xref>,<xref rid="B102-biomedicines-08-00060" ref-type="bibr">102</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreas [<xref rid="B103-biomedicines-08-00060" ref-type="bibr">103</xref>]<break/>Prostate [<xref rid="B104-biomedicines-08-00060" ref-type="bibr">104</xref>]<break/>Colon [<xref rid="B105-biomedicines-08-00060" ref-type="bibr">105</xref>]<break/>Glioblastoma [<xref rid="B106-biomedicines-08-00060" ref-type="bibr">106</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="biomedicines-08-00060-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">biomedicines-08-00060-t002_Table 2</object-id><label>Table 2</label><caption><p>Clinical trials of melanoma treatment using oncolytic viruses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trial</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Results</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved durable response rate (16.3% vs. 2.1%), overall response rate (26.4% vs. 5.7%) and longer median survival (patients with non-surgically resectable melanoma) [<xref rid="B116-biomedicines-08-00060" ref-type="bibr">116</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-biomedicines-08-00060" ref-type="bibr">116</xref>,<xref rid="B117-biomedicines-08-00060" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase Ib/II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50% objective response rate<break/>44% of patients had a durable response lasting &#x0003e;6 months</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-biomedicines-08-00060" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV T-VEC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II/IIIb</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overall survival superior for patients with stage III and IV M1a melanoma<break/>Significant clinical benefits in phase III</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-biomedicines-08-00060" ref-type="bibr">114</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reovirus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No objective responses seen</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-biomedicines-08-00060" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coxsackievirus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase Ib</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stable disease in 26.7% of patients<break/>Best ORR of 60%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-biomedicines-08-00060" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coxsackievirus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Durable responses in melanoma metastases (injected and uninjected)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-biomedicines-08-00060" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Newcastle Disease Virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II/III</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No superiority compared to controls</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-biomedicines-08-00060" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alphaviruses</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10-fold enhanced IL-12 plasma levels<break/>Encapsulation enhanced tumor targeting</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-biomedicines-08-00060" ref-type="bibr">121</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>